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SUMMARY 
 
Despite therapeutic innovations, metastatic colorectal cancer (mCRC) is still 
characterized by poor prognosis. Few molecular markers are available to predict 
progression risk and to help therapeutic decisions. Polycomb group genes (PcGs) are 
epigenetic modifiers involved in tumor suppressor gene silencing. EZH2 is a PcG 
member that mediates gene silencing through histone-H3 lysine-27 methylation. In 
CRC, EZH2 over-expression is associated to shorter survival. Recently, 4 EZH2 
single nucleotide polymorphisms (SNPs) have been characterized: the present study 
aimed at evaluating the correlation between EZH2 SNPs and outcome parameters in 
mCRC patients. 
DNA was extracted from blood samples of 110 mCRC patients treated with first-line 
FOLFIRI plus bevacizumab, and 104 mCRC patients treated with FOLFIRI. 
Genotyping was performed by Real-Time PCR. Allelic variant distribution was used 
to predict objective response, progression-free survival (PFS) and overall survival 
(OS).  EZH2 mRNA levels were evaluated on lymphocytes of a parallel cohort of 50 
radically resected stage II or III CRC patients. 
One allelic variant (rs3757441 C/C vs. C/T or T/T) was significantly associated to 
shorter PFS and OS in both mCRC patient cohorts receiving first-line FOLFIRI (with 
or without bevacizumab). At multivariate analysis, the same variant resulted an 
independent predictor of both PFS and OS (p<0.05). Among the 50 patients analysed 
for EZH2 expression and genotyped for EZH2 rs3757441 SNP, mRNA levels were 
significantly higher in patients harbouring the C/C genotype with respect to C/T and 
T/T (p<0.05), with no difference between C/T and T/T genotypes.  
  vi 
Our results indicate that an EZH2 SNP may be useful to predict PFS and OS in 
mCRC patients treated with first-line FOLFIRI (with or without bevacizumab).  
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CHAPTER 1. INTRODUCTION 
 
 
 
1.1. Treatment of metastatic colorectal cancer: state of the art 
 
Colorectal cancer (CRC) still represents the third most common malignancy 
and the second leading cause of cancer death in Western countries1: about 30.000 
new cases and over than 15.000 deaths have been recorded in Italy in 20002. Even if 
in the 90% of the cases a radical resection of the primary tumor is possible, 25% of 
patients present with metastatic disease at diagnosis and 50% die from systemic 
disease3.  
In the last decade, great advances have been achieved in the treatment of 
metastatic CRC (mCRC): thanks to the availability of a greater number of effective 
cytotoxic and targeted agents and to the higher percentage of patients who undergo 
radical resection of metastases, overall survival (OS) has approached 24 months in 
most recent trials, and definitive cure of the disease is a realistic aim of treatment in 
at least 10-15% of the patients4,5. Moreover, together with the introduction of new 
drugs into clinical practice, new strategies have been developed, and therapeutic 
approach toward mCRC patients is growingly individualized according to the goal of 
treatment itself (palliation, long-term OS or cure)6,7. In the following paragraphs we 
will discuss the current data supporting the use of cytotoxic and targeted agents in 
the treatment of mCRC and review the role of the available prognostic and predictive 
biomarkers in individualising treatment algorithm in different patient subsets.   
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1.1.1. Role of chemotherapy in metastatic colorectal cancer 
 
For over than 30 years 5-fluorouracil (5-FU) has been the only available 
treatment for which reliable data supported a role in mCRC: a meta-analysis8 of 
various randomized trials has demonstrated that 5-FU improves OS and quality of 
life (QoL) of mCRC patients compared to best supportive care (BSC) alone and a 
randomized trial demonstrated that the advantage is greater when chemotherapy is 
started early in the course of the disease, before the onset of symptoms9.   
The introduction of irinotecan and oxaliplatin improved the antitumor activity 
and the efficacy of chemotherapy in this disease7. The combinations of irinotecan 
plus either infusional or bolus 5-FU/leucovorin (LV) (FOLFIRI and IFL, 
respectively) and oxaliplatin plus infusional 5-FU/LV (FOLFOX) have demonstrated 
increased activity and efficacy compared with 5-FU/LV alone in randomized 
studies10,11,12,13. Of interest, phase III studies comparing irinotecan plus 5-FU/LV 
with 5-FU/LV alone suggested that a more active treatment administered upfront can 
prolong OS, even if active second-line therapies are offered to patients progressing 
on 5-FU/LV. Furthermore, studies with oxaliplatin plus 5-FU/LV have indicated that 
a highly active first-line chemotherapy regimen may permit, in a small subgroup of 
initially unresectable mCRC patients, a secondary radical surgical approach on 
metastases after response to chemotherapy, and that approximately 30% to 40% of 
operated patients will survive without evidence of disease for more than 5 years14,15. 
Therefore, taken together these data indicate that in mCRC a more active first-line 
treatment can be more effective, and a meta-analysis of 25 randomized trials of first-
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line treatment also supports the relationship between tumor response to first-line 
chemotherapy and OS16.  
More recently, a randomized study by the GERCOR group17 assigned 220 
untreated mCRC patients to receive first-line FOLFIRI followed by FOLFOX-6 at 
progression (arm A), or the reverse (arm B). Both sequences achieved similar 
activity and efficacy, and, of interest, median OS was 21.5 months in arm A and 20.6 
months in arm B, which are among the highest survival times reported up to now in 
any randomized study of chemotherapy alone in mCRC. This study suggests that the 
exposure of mCRC patients to all the three most active agents (i.e. 5-FU/LV, 
irinotecan and oxaliplatin) is associated with best survival outcome. In addition, a 
study by Goldberg et al.18 demonstrated the superiority of the FOLFOX-4 regimen to 
IFL and confirmed the importance of the three-drug exposure, considering that in the 
IFL arm only 24% of patients could receive oxaliplatin as second-line treatment, 
while in the FOLFOX-4 arm 60% of patients were able to receive salvage treatment 
with irinotecan. These data are in line with the results of a recent pooled analysis of 
seven phase III trials demonstrating that OS is correlated with the proportion of 
patients who received all the three active drugs in the course of their disease, but not 
with the proportion of patients who received any second-line therapy19.   
Another relevant advance in the management of mCRC is the availability of 
the oral fluoropyrimidine capecitabine. A meta-analysis of the studies comparing 
capecitabine plus oxaliplatin (CAPOX) with FOLFOX demonstrated that 
capecitabine is non-inferior to 5-FU in terms of PFS and OS, but results in a 
significantly lower RR20. Conversely, the results reported with capecitabine plus 
irinotecan (CAPIRI) are controversial, underlining that oral chemotherapy needs 
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active patient management. In fact, the EORTC 40015 trial21 was prematurely 
suspended due to alarming safety concerns: CAPIRI reported an unacceptably higher 
rate of grade 3-4 diarrhoea compared to FOLFIRI (37% vs. 13%), with an increased 
incidence of treatment-related deaths (5 vs. 2 patients). As a consequence, both PFS 
(5.9 vs. 9.6 months) and OS (14.8 vs. 19.9 months) were shorter with CAPIRI. In the 
BICC-C study22,23 CAPIRI reported shorter median PFS when compared with 
FOLFIRI (5.8 vs. 7.6 months; HR=1.36, p=0.015) and higher rates of severe events, 
particularly diarrhoea (47.5% vs. 13.9%) and dehydration (19.1% vs. 5.8%). On the 
contrary, the CAIRO trial24 completed accrual and demonstrated an acceptable rate 
(26%) of grade 3-4 diarrhoea. All these trials tested the same CAPIRI schedule, so 
such differences in tolerability cannot be merely explained by differences in the dose 
intensity of chemotherapy. One possible confounding factor in the EORTC 40015 
and BICC-C studies is represented by a second randomisation to either celecoxib or 
placebo, since coxibs have been associated with an increased risk of toxicities 
(particularly cardiovascular thrombotic events) in CRC patients: however, a 
causative role of celecoxib in explaining the observed high rate of severe diarrhoea 
appears unlikely since this agent seems to protect against irinotecan-induced mucosal 
injury25. 
In order to expose all patients to 5-FU/LV, irinotecan and oxaliplatin (thus 
overcoming the risk not to receive active cytotoxics in second-line in case of rapid 
disease progression and patient conditions deterioration) and in order to improve the 
activity of treatment (thus potentially increasing the rate of secondary surgery of 
metastases26), the Gruppo Oncologico Nord Ovest (G.O.N.O.) developed the triplet 
regimen named FOLFOXIRI which proved to be feasible with acceptable toxicities 
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and promising activity and efficacy in phase I-II studies27,28. When compared with 
FOLFIRI in a randomized phase III trial29, FOLFOXIRI confirmed to be feasible and 
resulted in higher RR (66% vs. 41%, p=0.0002) and radical resection rate of 
metastases (15% vs. 6% of patients, p=0.033). Moreover, at a median follow-up of 
18.4 months 216 patients have progressed and median PFS and OS were 
significantly longer in the FOLFOXIRI arm (9.8 vs. 6.9 months, p=0.0006 and 22.6 
vs. 16.7 months, p=0.032, respectively) with a HR of 0.60 in favour of FOLFOXIRI. 
Finally, the rate of early progressions (within 6 months from treatment onset) was 
significantly lower in the FOLFOXIRI arm (18% vs. 45%, p<0.0001). A recent 
update of the trial30 confirmed the PFS (median: 9.8 vs. 6.8 months, HR=0.59, 
p<0.0001) and OS (median: 23.4 vs. 16.7 months, HR=0.74, p=0.026; 5-year 
survival rate: 15% vs. 8%) benefit for the triplet at a median follow up of 60.6 
months. The authors concluded that the FOLFOXIRI regimen is feasible with 
manageable toxicities also in a multicenter setting: the incidence of grade 3-4 
neutropenia and grade 2-3 peripheral neurotoxicity is increased with FOLFOXIRI, 
but febrile neutropenia, diarrhoea and other toxicities are comparable to FOLFIRI. 
As recently reported by the same group, the benefit derived from the triplet is not 
entirely due to the increased rate of secondary radical surgery: in fact, FOLFOXIRI 
retained its superiority also when resected patients were excluded from the analysis, 
confirming a better palliative effect in unresectable mCRC than FOLFIRI. Moreover, 
such an aggressive strategy does not harm the feasibility and the efficacy of salvage 
therapies with the same agents used in first-line. The G.O.N.O. group conducted a 
phase I-II trial in order to evaluate capecitabine instead of 5-FU in a triplet regimen 
(XELOXIRI), but the change from infusional to oral fluoropyrimidine resulted in 
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increased rate of severe diarrhoea, confirming that capecitabine is not a preferable 
alternative to 5-FU in both irinotecan-containing doublet and triplet regimens.  
Another phase III trial by the Hellenic Oncology Research Group (H.O.R.G.) 
evaluated the triple combination in the first-line treatment of mCRC patients31. 
Results demonstrated a non-significant trend for superiority for the FOLFOXIRI 
regimen compared to FOLFIRI, both in terms of activity (RR: 33.6% vs. 43%; 
secondary R0 metastasectomy: 4% vs. 10%) and efficacy (median TTP: 6.9 vs. 8.4 
months; median OS: 19.5 vs. 21.5 months). These apparent discrepancies between 
the G.O.N.O. and H.O.R.G. trials can be explained by differences in treatment 
schedules and study populations. In fact, the G.O.N.O. regimen allows to avoid the 
5-FU bolus administration and to administer a higher dose intensity of 5-FU, 
irinotecan and oxaliplatin, compared with the H.O.R.G. schedule (1600 
mg/sqm/week vs. 1000 mg/sqm/week; 82.5 mg/sqm/week vs 75 mg/sqm/week; and 
42.5 mg/sqm/week vs. 32.5 mg/sqm/week, respectively). As regards patient 
characteristics, patients aged more than 75 years were not included in the G.O.N.O. 
trial and if aged 70-75 an ECOG PS of 0 was required, while the H.O.R.G. study had 
no upper age limit (age range reached 82 years in the FOLFOXIRI arm) and elderly 
(more than 70-year old) patients with poor PS (1-2) were eligible: indeed, study 
population in the H.O.R.G. trial was older (median age: 66 vs. 62 years, respectively) 
and with a poorer performance status (ECOG PS 0/1/2: 36/53/11% in the H.O.R.G. 
trial vs. 61/37/2% in the G.O.N.O. trial). All these factors could have contributed to 
the different results of the triple regimens and underlined the need for adequate 
selection of fit patients when intensive chemotherapy is administered. Indeed, the 
potentials of the upfront triple strategy have been confirmed by the meta-analysis of 
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the G.O.N.O. and H.O.R.G. trials reported by Golfinopoulos et al.32, who 
demonstrated significant advantages for FOLFOXIRI compared to FOLFIRI both in 
terms of disease progression and survival. 
Masi et al.33 recently published the results of a retrospective pooled analysis on 
196 patients treated with first-line FOLFOXIRI in order to evaluate the long-term 
outcome of patients radically resected after chemotherapy. Thirty-seven (19%) could 
undergo a secondary R0 surgery on metastases (complete pathological response has 
been achieved in 4 patients) after a median of 5.5 months of treatment. The authors 
reported no intra-operative or post-operative mortality and a low rate of peri-
operative complications (27% of cases), all of which were transient and resolved 
completely. After a median follow-up of 67 months, 5-year and 8-year OS were 42% 
and 33%, respectively. At 5 years, 29% of the resected patients were free of 
progression. Such results demonstrated the feasibility and the efficacy of 
FOLFOXIRI as conversion therapy and were consistent with the observation of 
Folprecht et al.26 that more active first-line treatments result in a higher secondary 
resection rate of metastases. 
If the abovementioned results support the role of a more intense first-line 
approach, several randomized phase III trials addressed the question whether all 
mCRC patients should receive upfront combination chemotherapy. In the CAIRO 
study24, 820 patients were randomized to first-line capecitabine, second-line 
irinotecan, and third-line CAPOX or first-line CAPIRI and second-line CAPOX. The 
trial was powered to detect a superiority of the combination over single-agent based 
on an anticipated median OS of 14.0 vs. 17.5 months, but did not demonstrate any 
difference in OS, the primary end point (16.3 months for the sequential treatment 
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group vs. 17.4 months for the combination group; HR 0.92, 95%CI 0.79-1.08, 
p=0.3281), despite increased RR (41% vs. 20%, p<0.0001) and PFS (median: 7.8 vs. 
5.8 months; HR 0.77, 95%CI 0.67-0.89; p=0.0002) being reported with the upfront 
combination. The FOCUS trial34 randomized over 2100 patients to three different 
strategies: 5-FU/LV followed by irinotecan (strategy A); 5-FU/LV followed by 
FOLFIRI/FOLFOX (strategy B); first-line FOLFIRI/FOLFOX followed by the 
reverse regimen at progression (strategy C). FOCUS aimed to show non-inferiority 
of the single-agent approach. Again, the authors did not report OS differences among 
study arms (strategy C vs. B, median: 15.9 vs. 15.1 months; HR 1.06, 90%CI 0.97-
1.17), while higher RR (5-FU/LV vs. FOLFIRI or FOLFOX: 28% vs. 49% or 57%, 
p<0.001) and PFS (5-FU/LV vs. FOLFIRI or FOLFOX: 6.3 vs. 8.5 or 8.7 months, 
p<0.001) were achieved with combination therapy, at the price of increased but 
acceptable toxicity: data from FOCUS therefore exclude a reduction of more than 
5% in 2-year survival or a difference in median OS of more than 2.3 months with the 
upfront use of single-agent chemotherapy. Even though both CAIRO and FOCUS 
reported median OS in the range of 13.9-17.4 months, which is less than expected in 
patients treated with a sequence of doublet regimens (approximately 20 months), 
several factors contribute to explain this finding: the poor prognosis of the patients 
enrolled (in fact, potentially resectable patients were excluded in the FOCUS trial) 
and the small proportion of patients who received all the three active agents after 
initial treatment with monotherapy (in the range of 19-55%).  
Among elderly or unfit patients, the recently published FOCUS-2 trial35 
demonstrated that the addition of oxaliplatin to fluoropyrimidine increases RR, with 
a trend toward higher PFS and equal OS, compared with single-agent 
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fluoropyrimidine. After comprehensive health assessment, 459 patients were 
randomly assigned to one of the following arms: 5-FU/LV (group A); oxaliplatin and 
5-FU (group B); capecitabine (group C); or oxaliplatin and capecitabine (group D). 
The trial investigated whether the addition of oxaliplatin ([A vs. B] + [C vs. D]) to 
fluoropyrimidine is beneficial in terms of PFS and whether the substitution of 5-FU 
with capecitabine ([A vs. C]+[B vs. D]) improves QoL, as assessed by change from 
baseline to 12 weeks in global QoL. Final results demonstrate that a non-significant 
improvement in median PFS can be achieved with the upfront combination regimen 
(5.8 vs. 4.5 months; HR 0.84, 95%CI 0.69-1.01, p=0.07), while replacing 5-FU with 
capecitabine does not result in improved global QoL (56% patients receiving 5-FU 
reported improvement in global QoL compared with 56% receiving capecitabine): 
however, the incidence of grade 3 or worse toxicities, while not significantly 
increased with oxaliplatin (38% vs. 32%, p=0.17), was higher with capecitabine than 
with 5-FU (40% vs. 30%, p=0.03). Again, even in FOCUS-2 OS did not differ 
between monotherapy and combination groups (HR 0.99, 95%CI 0.81-1.18, p=0.91). 
Taken together, these data underline a key issue in mCRC patient management, 
i.e. the importance to target the intensity of first-line chemotherapy on the basis of 
both patient and disease characteristics and the aim of treatment. In fact, if 
comorbidities or advanced age might impair the feasibility of more intense 
chemotherapy in some patients, disease burden might require (or not) the need for a 
rapid tumor response in others. Again, in selected cases a more active treatment 
might be the best choice to achieve enough tumor shrinkage and allow a radical 
secondary resection of metastases. We have convincing evidence that an upfront 
combination regimen achieves superior RR, secondary surgery of metastases rate and 
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PFS at the price of acceptable toxicity: for these reasons, patients with potentially 
resectable disease or with high tumor burden or disease-related symptoms may 
benefit from a more active combination regimen. On the other hand, data from phase 
III trials support the use of sequential single-agent chemotherapy in those cases with 
more indolent disease course, when the objective is prolonging OS without impairing 
QoL with consistent toxicities.  
If the intensity of the upfront strategy may differ in different patient subgroups, 
however, several randomized trials convincingly demonstrated that scheduled 
treatment duration or pauses after a predefined period of treatment do not impair 
results in terms of OS and might contribute to improve treatment tolerability. The 
OPTIMOX-1 trial36 was the one of the first large study suggesting that prolonging 
combination chemotherapy is not necessary in mCRC: investigators randomized 620 
patients to FOLFOX-4 until progression or FOLFOX-7 for 12 weeks followed by 5-
FU/LV (with oxaliplatin reintroduced at progression). The median duration of 
disease control (DDC, the primary end point, defined by the authors as PFS, or, if 
FOLFOX was reintroduced, addition of the initial PFS and the PFS of the 
reintroduction, except in case of progression at the first evaluation after FOLFOX 
reintroduction) did not differ between the two arms (9.0 vs. 10.6 months, HR 0.99, 
95%CI 0.81-1.15, p=0.89) and also PFS and OS times were comparable between the 
continuous and the maintenance treatment arms (median PFS: 9.0 vs. 8.7, HR 1.06, 
95%CI 0.89-1.20, p=0.47; median OS 19.3 vs. 21.2, HR 0.93, 95%CI 0.72-1.11, 
p=0.49), as was RR (58.5% vs. 59.2%, p=NS). Among patients allocated to 
maintenance 5-FU treatment, there was a trend toward reduced incidence of grade 3 
oxaliplatin-related neurotoxicity (13.3% vs. 17.9%, p=0.12). 
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After this pivotal experience, two trials tested chemotherapy-free intervals 
during first-line therapy. The randomized phase II OPTIMOX-2 study37 compared 
stop-and-go FOLFOX-7 (as tested in OPTIMOX-1) with FOLFOX-7 for 3 months 
followed by an observation period of 3 months (with the same regimen reintroduced 
at progression): the median DDC (primary end point) and median PFS were 
significantly longer in the maintenance arm (13.1 and 8.6 months, respectively) than 
in the chemotherapy-free interval arm (9.2 and 6.6 months, respectively) (HR=0.71, 
p=0.046 for DDC comparison; HR=0.61, p=0.0017 for PFS comparison), and a trend 
toward decreased OS was observed in the experimental arm (median: 19.5 vs. 23.8 
months, HR 0.88, p=0.42; 2-year survival rate: 39.4% vs. 50%). Even though with 
several limitations due to the study design and sample dimension, OPTIMOX-2 
seems to suggest that a maintenance treatment with a fluoropyrimidine may help in 
maximizing the benefit of upfront combination regimens, while a complete 
interruption of chemotherapy may be detrimental. 
Similar data have been reported by Maughan et al.38 who have recently 
published the final results of the COIN trial. Two of the three arms of the trial 
answered the question whether intermittent combination chemotherapy (XELOX or 
mFOLFOX for 12 weeks, than stopped and restarted at disease progression for a 
further 12 weeks of treatment) is non-inferior in terms of OS to continuous 
combination chemotherapy until progression. Investigators randomized 1630 patients 
and demonstrated that median OS achievable with intermittent chemotherapy is non-
inferior to the one reported by continuous treatment (14.4 vs. 15.8 months; HR 1.084, 
80%CI 1.008-1.165) (according to the study design, however, results reliably 
exclude a detriment larger than 10 weeks in median OS). Intermittent chemotherapy 
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allowed a median time interval free from chemotherapy of 3.7 months and 
significantly reduced toxicity, particularly grade 3 or more peripheral sensory 
neuropathy.  
More convincingly, results of the recently published phase III GISCAD trial39 
suggest that comparable outcome can be achieved with continuous and intermittent 
(2 months on, 2 months off) FOLFIRI in first-line: among the 337 randomized 
patients, author reported equal OS results (primary endpoint) (18 months in the 
intermittent chemotherapy arm vs. 17 months in the continuous chemotherapy arm, 
HR 0.88, 95%CI 0.69-1.14). Also PFS was comparable in the two groups (6 months 
in both, HR 1.03, 95%CI 0.81-1.29), and no difference was reported even in terms of 
RR (34% vs. 42%, p=0.192). The median chemotherapy-free period in the 
intermittent arm was 3.5 months, in line with the data reported by COIN 
investigators with an oxaliplatin-based regimen. In the Italian trial the incidence of 
grade 3-4 toxicity was similar between arms, but this was not unexpected since main 
adverse events were represented by acute toxicities such as myelosuppression, fever 
and diarrhoea, rather than cumulative toxicity (such as oxaliplatin-induced 
neurotoxicity). 
 
 
1.1.2. Role of bevacizumab in metastatic colorectal cancer 
 
Vascular endothelial growth factor (VEGF) plays a crucial role in the 
development of new blood vessels in both healthy tissues and tumors. Its effect is 
mainly mediated through binding to the VEGF receptor-2, found predominantly on 
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the surface of the vascular endothelial cells. Induction of the intracellular tyrosine 
kinase activity of receptor by VEGF binding triggers the phosphorylation of a 
multitude of proteins with a subsequent cascade of intracellular signalling 
pathways40. VEGF plays a number of key roles in the pathogenesis of cancer: 
through excessive and deregulated angiogenesis, not only it allows the tumor to 
embark upon its exponential growth phase, but also provides an exit route for 
haematogenous metastases and allows them to establish themselves in distant 
organs41. 
Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that 
binds to and inhibits the biologic activity of human VEGF in in vitro and in vivo 
assay systems. Bevacizumab contains human framework regions and the 
complementarity-determining regions of a murine antibody that binds to VEGF42. 
Hurwitz et al.43 conducted a randomized phase III trial evaluating the addition 
of bevacizumab to first-line irinotecan-based treatment of mCRC patients. A total of 
813 patients were randomly assigned to receive bolus IFL plus placebo, bolus IFL 
plus bevacizumab, or 5-FU/LV plus bevacizumab. Enrolment in the latter arm was 
discontinued, as pre-specified, when the toxicity profile of bevacizumab in 
combination with the bolus IFL regimen was deemed acceptable. The addition of 
bevacizumab to IFL significantly improved RR (44.8% vs. 34.8%; p=0.004), PFS 
(10.6 months vs. 6.2 months; HR 0.54, p<0.001) and OS (20.3 months vs. 15.6 
months; HR=0.66, p<0.001), the primary end point of the trial. In terms of toxicity, 
adding bevacizumab to chemotherapy significantly increased the incidence of grade 
3 hypertension (11% vs. 2.3%, p<0.01), but interestingly it did not impact 
significantly upon the rates of proteinuria, thrombosis and bleeding. Six 
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gastrointestinal perforations occurred in patients receiving IFL plus bevacizumab. 
The results of this study demonstrated a significant improved activity and efficacy of 
the combination of bevacizumab with IFL in comparison to chemotherapy alone with 
manageable toxicities.  
In the NO16966 study44 about 1400 mCRC patients were randomized to 
receive chemotherapy (FOLFOX or XELOX) plus bevacizumab or chemotherapy 
(FOLFOX or XELOX) plus placebo as first-line treatment. The primary end point of 
this phase III study was PFS: the addition of bevacizumab to oxaliplatin-based 
regimens significantly increased PFS in comparison to chemotherapy alone (9.4 
months vs. 8.0 months; HR 0.83, 97.5%CI 0.72-0.95, p=0.0023). Median OS was 
21.3 months in the bevacizumab group and 19.9 months in the placebo group: this 
difference did not reach statistical significance (HR 0.89, 97.5%CI 0.76-1.03, 
p=0.077). RR was also superimposable in the two groups. The magnitude of the 
effect of bevacizumab seemed relatively less impressive if compared with that 
reported by Hurwitz and colleagues. As specified by the authors and suggested by 
Giantonio at the 2007 ASCO Annual Meeting45, the main explanation could be the 
frequent discontinuation of bevacizumab plus chemotherapy before disease 
progression (in 71% of patients), which seems not to be related to unexpected 
adverse events. In fact, the toxicity profile of bevacizumab was in line with the data 
obtained in previous trials: the incidence of grade 3-4 thromboembolic events, 
hypertension and bleeding was 10%, 4% and 2% respectively, while grade 3-4 
gastrointestinal perforations, proteinuria and wound healing complications were rare 
(<1%). Treatment discontinuation because of adverse events was reported in 30% of 
patients receiving bevacizumab. 
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The importance of maintaining bevacizumab until disease progression even if 
chemotherapy is stopped has been recently underlined by the MACRO trial46. 
Investigators randomized 480 patients to receive 6 cycles of XELOX plus 
bevacizumab followed by the same regimen or bevacizumab alone until disease 
progression. The trial suggested that bevacizumab could be non inferior to 
maintenance XELOX plus bevacizumab in terms of PFS (primary end point), since a 
detriment larger than 3 weeks with bevacizumab alone can be excluded, even though 
non-inferiority was not formally demonstrated (median PFS: 11.0 vs. 10.3 months, 
HR 1.07, 95%CI 0.84-1.36; upper non inferiority limit according to study design: 
1.32). As reported by the studies evaluating optimal duration of chemotherapy alone, 
even in the MACRO trial patients in the single-agent bevacizumab arm experienced 
less grade 3-4 neurotoxicity and hand-and-foot syndrome.  
The G.O.N.O. group conducted a phase II trial47 in order to evaluate the 
combination of bevacizumab with the FOLFOXIRI regimen repeated every 2 weeks, 
for a total of 12 cycles, followed by a maintenance treatment with bevacizumab with 
or without 5-FU/LV. A total of 57 unresectable mCRC patients were enrolled. 
Objective response was obtained in 77% of patients and radical surgery of metastases 
was performed in 26% of patients (43% in patients with liver-only metastases). After 
a median follow-up of 18.4 months, median PFS was 13.4 months. The most 
common grade 3-4 bevacizumab-related toxicities were deep venous thrombosis 
(5%) and hypertension (11%). Results of this study are very promising and suggest 
that bevacizumab can be safely combined with the G.O.N.O. FOLFOXIRI regimen 
with manageable toxicities: in order to confirm these preliminary results and 
compare a triplet regimen plus bevacizumab with a standard doublet chemotherapy 
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(FOLFIRI) plus the same antiangiogenic agent, a phase III trial is currently ongoing 
and has recently completed accrual. 
 
 
1.1.3. Role of anti-EGFR agents in metastatic colorectal cancer 
 
Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein 
with an intracellular tyrosine kinase domain. Binding of specific ligands, such as 
epidermal growth factor (EGF) or transforming growth factor alpha (TGF-α), to the 
receptor causes the dimerization of single-chain EGFR and subsequent activation of 
receptor autophosphorylation through tyrosine kinase activity48. These molecular 
events initiate a cascade of intracellular signalling pathways, which ultimately 
regulate cancer cell proliferation and differentiation, apoptosis and survival, invasion 
and metastatic potential and tumor-induced neovascularisation. 
Considering that deregulation of EGFR-controlled pathways is a common 
phenomenon in human epithelial carcinogenesis, EGFR was the first growth factor 
receptor to be proposed as a target for cancer therapy. Up today, two different classes 
of EGFR-inhibitors have been developed and successfully tested in clinical trials for 
malignancies of different origin: anti-EGFR monoclonal antibodies and small-
molecule EGFR tyrosine kinase inhibitors49.  
Two anti-EGFR monoclonal antibodies are currently approved for the 
treatment of mCRC: cetuximab and panitumumab. Cetuximab is a chimeric IgG1 
monoclonal antibody that competitively inhibits endogenous EGF/TGF-α binding 
targeting the EGFR extracellular domain with a consequent inhibition of cancer cell 
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proliferation and induction of apoptosis. Panitumumab is a fully humanized IgG2 
monoclonal antibody that elicits a minimal immunogenic response, thus reducing the 
risk of hypersensitivity reactions. However, IgG2 antibodies are not able to induce 
antibody-dependent cell-mediated cytotoxicity (ADCC): the clinical impact of 
ADCC is not fully understood, but it is thought to contribute to the antitumor activity 
of IgG1 antibodies49. 
Recently, deeper insights into EGFR biology have led to the identification of 
KRAS mutational status as a key determinant of sensitivity to anti-EGFR treatment in 
mCRC50 (see paragraph 1.2. for details). In fact, it is now well established that 
benefit from both cetuximab and panitumumab is limited to the KRAS wild-type 
population, while KRAS mutant tumors are resistant to anti-EGFR agents. This is 
particularly true for the most common mutations at codons 12 and 13, while for less 
frequent mutations the available evidence is less conclusive. 
Several trials established the role of anti-EGFR agents in different lines of 
treatment in mCRC. The CRYSTAL study51,52, a randomized phase III study 
evaluating FOLFIRI with or without cetuximab, demonstrated significant 
improvement for the experimental arm in RR (57.3% vs. 39.7%; p<0.0001), PFS (9.9 
vs. 8.4 months; HR 0.696, 95%CI 0.558-0.867, p=0.0012) and OS (23.5 vs. 20.0 
months; HR 0.796, 95%CI 0.670-0.946, p=0.0093) among KRAS wild-type patients. 
Interestingly, among patients with liver-limited disease RR increased from 44.4% to 
70.6% with the addition of cetuximab to FOLFIRI. As regards secondary resection 
rate53, cetuximab had a positive impact in patients unselected for KRAS mutations, 
since 7.0% of patients in the anti-EGFR arm were resected compared to 3.7% with 
FOLFIRI alone and R0 resection rates were 4.8% and 1.7%, respectively (p=0.002). 
  18 
Among KRAS wild-type patients, radical surgery was achieved in 5.1% of patients 
treated with cetuximab compared with 2.1% of patients treated with chemotherapy 
alone (p=0.027), and for patients with liver-only metastases the percentages raise to 
13.2% and 5.6%, respectively (p=0.15). The toxicity profile of the combination 
treatment, cetuximab plus FOLFIRI, was in line with that expected: the incidence of 
grade 3 skin reactions, mainly acne-like rash, was significantly higher in patients 
receiving the anti-EGFR antibody in comparison with those receiving FOLFIRI 
alone (skin reactions: 19.7% vs. 0.2%, p<0.001; acne-like rash: 16.2% vs. 0.0%; 
p<0.001). None of the skin-related toxicities reported were grade 4 and, in the 
cetuximab-treated group, grade of rash was shown to be associated with PFS. Also 
the incidence of grade 3-4 diarrhoea (15.7% vs. 10.5%; p=0.008) and infusion-
related reactions (2.5% vs. 0.0%; p<0.001) was significantly increased in the 
cetuximab-FOLFIRI group. However, these toxicities were manageable and the 
combination treatment appeared feasible. 
With regard to oxaliplatin-based chemotherapy, the most interesting results are 
those reported by the investigators of the randomized phase II OPUS trial54,55: among 
the 337 patients enrolled, there was a trend in favour of the cetuximab-containing 
arm compared to the FOLFOX-4 arm in terms of RR (46% vs. 36%; p=0.064), with 
super-imposable outcome in terms of PFS (median: 7.2 vs. 7.2 months; HR 0.931, 
95%CI 0.705-1.230, p=0.62). When analysis was limited to the 179 patients with 
KRAS wild-type tumor, results achieved statistical significance in favour of 
cetuximab both in terms of RR (57% vs. 34%, p=0.0027) and PFS (median: 8.3 vs. 
7.2 months; HR 0.567, 95%CI 0.375-0.856, p=0.0064). Interestingly, in contrast with 
the CRYSTAL trial, OPUS showed significantly poorer results in terms of activity 
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(RR: 34% vs. 53%, p=0.0290) and efficacy (median PFS: 5.5 vs. 8.6 months; HR 
1.720, 95%CI 1.104-2.679, p=0.0153) for the cetuximab-containing arm among the 
136 patients with a KRAS mutant tumor. Again, OPUS confirmed that a cetuximab-
based treatment may be interesting in increasing the percentage of KRAS wild-type 
patients converted to resectability over chemotherapy alone (7.3% vs. 3.1%, p=0.22; 
in patients with liver-only metastases: 16% vs. 4.3%, p=0.35), even though data from 
such limited subgroups should be interpreted with caution. 
Folprecht et al.56 reported the results of the phase II CELIM trial, which 
randomized 111 patients with unresectable liver metastases to receive cetuximab 
with either FOLFOX-6 or FOLFIRI. In contrast with the unselected populations 
enrolled in CRYSTAL and OPUS, CELIM investigators excluded patients with 
extra-hepatic disease and precisely defined criteria for non-resectability (i.e. five or 
more liver metastases or liver metastases judged technically non-resectable by the 
local liver surgeon and radiologist on the basis of inadequate future liver remnant, 
infiltration of all hepatic liver veins, infiltration of both hepatic arteries or both portal 
vein branches). It should be noted that the trial did not enrol patients with potentially 
resectable liver metastases only: in fact, expected resectability was not considered an 
inclusion criterion and patients with extensive liver involvement were eligible. 
Resectability was re-assessed by a local multidisciplinary team using CT scans after 
8 cycles of treatment and, if not feasible, every 2 months thereafter. As regards the 
primary endpoint, FOLFOX-6 and FOLFIRI achieved comparable RR in 
combination with cetuximab in the KRAS unselected population (68% vs. 57%, 
p=0.23), resulting in similar R0 resection rates (38% vs. 30%, respectively). A 
retrospective review by independent surgeons was made on the scans performed 
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baseline and after treatment by 68 patients and clearly indicates that resectability 
rates increased from 32% to 60% (p<0.0001) as a consequence of treatment activity. 
Despite these intriguing results, treatment with anti-EGFR agents still has some 
dark sides that question the role of cetuximab and panitumumab in mCRC patients. 
The MRC COIN study57, a large phase III trial conducted in the United Kingdom, 
randomized 2445 unselected mCRC into three different arms: continuous 
fluoropyrimidine (5-FU/LV or capecitabine) and oxaliplatin, intermittent 
fluoropyrimidine and oxaliplatin or continuous fluoropyrimidine and oxaliplatin plus 
cetuximab. The trial tried to answer two different questions, i.e. whether intermittent 
chemotherapy is non-inferior in terms of OS to continuous chemotherapy and 
whether the addition of cetuximab improves OS compared to chemotherapy alone. 
As regards the latter question, among the 729 KRAS wild-type patients investigators 
failed to demonstrate a significant difference in favour of the cetuximab-containing 
arm compared to chemotherapy alone in terms of OS (median: 17.0 vs.19.9 months; 
HR 1.04, 95%CI 0.90-1.20; p=0.68) and PFS (median: 8.6 vs. 8.6 months; HR 0.959, 
95%CI 0.84-1.09; p=0.60), despite a marginally significant improvement in RR was 
proved (64% vs. 57%, p=0.049). Interestingly, a test for interaction suggested a 
differential effect for cetuximab on PFS according to the fluoropyrimidine 
administered (p=0.10), indicating a potential benefit in patients receiving 5-FU/LV 
and a detrimental effect with capecitabine: these data are confirmed by the authors 
by pooling the data of first-line trials with cetuximab both for PFS and OS. These 
results could possibly reflect the higher toxicity registered in the cetuximab arm 
when combined with XELOX, particularly in terms of severe mucosal injury (mainly 
grade 3 or more diarrhoea: 15% vs. 26%, p=0.0001) that led to a reduction in the 
  21 
dose of capecitabine during the study. Therefore, even in molecularly selected 
patients the addition of cetuximab to an oxaliplatin-based chemotherapy in a large 
trial failed to demonstrate significant advantage, with the exception of a marginal 
improvement in RR. As regards secondary resection of metastases, no increase in 
potentially curative liver surgery was identified, with resection rates among KRAS 
wild-type patients who had liver-only metastases at baseline of 13% (12 out of 91 
patients) in the control group and 15% (13 out of 87 patients) in the cetuximab group 
(p=0.74).  
In line with these results are those from the NORDIC VII trial58, which 
randomized 566 unselected mCRC patients to first-line therapy with a combination 
of bolus 5-FU and oxaliplatin (FLOX regimen), FLOX plus cetuximab until disease 
progression, or FLOX intermittently plus continuous cetuximab. The three arms 
achieved similar OS results, with no differences between continuous chemotherapy 
with or without cetuximab (19.7 vs. 20.4 months; HR 1.06; 95%CI, 0.83-1.35; 
p=0.67). Surprisingly, even among KRAS wild-type patients OS did not differ 
between these arms (20.1 vs. 22.0 months; HR 1.14, 95%CI 0.80-1.61, p=0.66), as 
did PFS (7.9 vs. 8.7 months, HR 1.07, 95%CI 0.79-1.45, p=0.66). It should be 
underlined however that sample dimension in NORDIC trial was not adequately 
powered for subgroup analysis. Anyway, NORDIC results stress the need for optimal 
companion chemotherapy with anti-EGFR agents in mCRC, and bolus 5-FU such as 
in the FLOX regimen is probably a not preferable schedule for combination with 
oxaliplatin.  
As previously discussed, triplet chemotherapy plus anti-EGFR may be a 
promising approach to maximize the activity of first-line treatment and possibly 
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increase the conversion to resectability rate. Up to now, data from phase II trials with 
different chemotherapy schedules are available. Garufi et al.59 recently reported the 
results of a triplet regimen with chrono-modulated irinotecan, 5-FU/LV and 
oxaliplatin (named chrono-IFLO) administered as neoadjuvant chemotherapy to 
increase the resectability of colorectal liver metastases in 43 initially unresectable 
mCRC patients due to extensive liver involvement or presence of extra-hepatic 
disease. Patients were not selected for KRAS status, but mutations were 
retrospectively evaluated in 37 out of 43 patients: 81% of analyzed samples were 
KRAS wild-type. The chrono-IFLO plus cetuximab combination achieved an 
interesting 79.1% RR, allowing radical resection of metastases in 26 patients (60%) 
after a median of 6 cycles before surgery, suggesting that a rapid shrinkage with a 
very active combination may shorten the duration of preoperative chemotherapy.  
A possible concern with the combination of triplet chemotherapy and anti-
EGFR agents is represented by the increased risk of mucosal toxicity: the POCHER 
trial reported a high rate of grade 3-4 diarrhoea (93% of patients), requiring dose 
reduction for all the cytotoxic agents. After dose reduction, incidence of diarrhoea 
decreased, but still occurred as grade 3-4 in 36% of treated patients, with an 
additional 26% of patients experiencing grade 2 diarrhoea: these results suggest that 
chrono-IFLO plus cetuximab is feasible, but requires adequate patient selection to 
avoid unacceptable toxicity.  
A French group60 tested cetuximab in combination with a more suitable triplet 
schedule for outpatient management (FOLFIRINOX) in a phase II trial in clinically 
and molecularly unselected mCRC patients aged 75 years or less and with good 
performance status, with complete RR as the primary end point. Preliminary 
  23 
interesting results have been presented: among 22 evaluable patients, 4 complete and 
18 partial responses were reported (RR, 82%). Gastrointestinal tolerability was 
greater than that reported by POCHER investigators: however, grade 3-4 diarrhoea 
and neutropenia (even despite primary G-CSF prophylaxis) still occurred in 35% and 
28% of the patients, respectively. Taken together, these two trials confirm that 
combining cetuximab with a three-drug regimen may result in consistent increase in 
activity, but efforts should be made in order to improve the feasibility of these 
regimens and better select patients on the basis of optimal staging techniques and 
molecular characterization.   
As regards panitumumab, final results of the phase III PRIME trial61 have been 
recently published. PRIME randomized 1183 unselected mCRC patients to first-line 
FOLFOX-4 with or without panitumumab and results of the study were 
prospectively analyzed by tumor KRAS status. In the wild-type KRAS population, 
adding panitumumab to chemotherapy significantly improved PFS (primary 
endpoint) compared with chemotherapy alone (median, 9.6 vs. 8.0 months; HR=0.80, 
95%CI 0.66-0.97, p=0.02), while a non-significant increase in OS was observed 
(median OS, 23.9 vs. 19.7 months; HR=0.83, 95% CI 0.67-1.02, p=0.072). As 
regards RR, despite a strong trend the increase in activity by the addition of 
panitumumab to chemotherapy did not reach statistical significance (55% vs. 48%; 
p=0.068). As a result, panitumumab plus FOLFOX-4 did not improve secondary 
resection rate over FOLFOX-4 alone: in fact, metastasectomy of any site was 
attempted in 10.5% of patients treated with the anti-EGFR agent and in 9.4% of 
patients treated with chemotherapy alone, while R0 resection was achieved in 8.3% 
and 7.0% of patients, respectively. As in other series, the addition of the anti-EGFR 
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antibody to oxaliplatin-based chemotherapy resulted in worse outcome in terms of 
PFS (median, 7.3 vs. 8.8 months; HR 1.29, 95%CI 1.04-1.62, p=0.02) and OS 
(median, 15.5 vs. 19.3 months; HR 1.24, 95%CI 0.98-1.57, p=0.068) among KRAS 
mutant patients.  
Globally considered, first-line trials testing anti-EGFR antibodies in mCRC 
demonstrate that the combination of such agents with chemotherapy may improve 
activity and, to a lesser extent and with less consistent results across trials, increase 
the efficacy of chemotherapy. If KRAS status evaluation is recognized as an essential 
element for treatment allocation, molecular refinement of patient selection may help 
to further improve the results of anti-EGFR agents. Moreover, companion 
chemotherapy is probably more relevant in order to maximize the benefit from these 
agents when compared to bevacizumab, as confirmed by COIN, PRIME and 
NORDIC trials which suggest oxaliplatin-based doublets as a not preferable 
alternative to irinotecan-containing ones. If the results of the OPUS and CELIM 
trials partially reassure about the possibility of adding an anti-EGFR antibody to an 
infusional 5-FU/LV and oxaliplatin (FOLFOX) regimen, results presented by the 
COIN and NORDIC investigators indicate that oxaliplatin plus either oral 
fluoropyrimidine (XELOX) or bolus 5-FU/LV (FLOX) should be avoided when 
patients are considered for a first-line cetuximab-containing combination.  
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1.2. Prognostic and predictive factors in metastatic colorectal cancer 
 
Together with improvements in the medical management of mCRC, deeper 
insights into the molecular basis of colorectal carcinogenesis have provided 
additional targets for new drug development and potential (or validated) predictive 
and prognostic biomarkers62,63. Despite these advances, however, our ability to 
predict disease course and patient response to treatments is relatively poor, and new 
hypothesis are being tested in order to optimize treatment decision in single cases. 
A comprehensive description of all the molecular variables evaluated as 
prognostic and predictive factors in mCRC is beyond the scope of this Introduction: 
we will therefore focus on the already validated biomarkers which have entered 
routine clinical practice and on the most promising alternatives which are still 
passing through the hard challenge of validation. 
The relevance of KRAS mutational status evaluation in mCRC patient 
candidate to anti-EGFR treatment has been already mentioned in the previous 
paragraph. Since the evaluation of EGFR expression by immunohistochemistry was 
not demonstrated as a useful tool to predict treatment efficacy64,65, many efforts have 
been made to identify potential predictors of benefit from anti-EGFR monoclonal 
antibodies. Attention has been therefore focused on intracellular mediators involved 
in the transduction of EGFR signal and both the KRAS/BRAF/MAPKs and the 
PTEN/PI3K/pAKT pathways have been investigated66. 
KRAS belongs to the RAS family of genes (comprising KRAS, NRAS, and 
HRAS) that encode guanosine-5´-triphosphate (GTP)-binding proteins. KRAS mainly 
acts as an effector of the ligand-bound EGFR through BRAF and the MAPK axis, but 
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can also activate PI3K through direct interaction with its catalytic subunit67. About 
32-40% of CRC cases harbour a KRAS mutation: most (85-90%) of these mutations 
occur in codons 12 or 13, with the remaining mainly occurring in codons 61 (5%) 
and 146 (5%)68. These mutations abolish the intrinsic GTPase activity of Ras protein, 
leading to the constitutive activation of the RAS/RAF/MAPKs cascade69: signalling 
events are thus independent from EGFR control, since KRAS accumulates in the 
active GTP-bound conformation. 
Several retrospective experiences70,71,72,73,74, then corroborated by the results of 
post-hoc analyses of large phase III randomized studies52,75,76, have evidenced the 
role of KRAS codon 12-13 activating mutations as predictors of resistance to anti-
EGFR antibodies. The abovementioned results of first-line trials are confirmed by 
the analysis of phase III trials that randomized heavily pretreated mCRC patients to 
anti-EGFR monotherapy or BSC alone: notably, results of these trials are not 
affected by the potential confounding effect of the associated chemotherapy 
regimens. When compared to BSC, both cetuximab and panitumumab demonstrated 
a survival benefit only for patients with KRAS wild-type tumors. No responders were 
identified among patients with KRAS mutated disease treated with panitumumab in 
comparison with the 17% of patients with KRAS wild-type tumors. Similar findings 
were reported in terms of PFS: the treatment effect in the KRAS wild-type (HR 0.45, 
95%CI 0.34-0.59) was significantly greater (p<0.0001) than in the mutant group (HR 
0.99, 95%CI 0.73-1.36)76. On the basis of these results, panitumumab was initially 
approved by regulatory authorities for the treatment of mCRC patients with KRAS 
wild-type disease77. Analogous results were obtained by the analysis of KRAS 
mutational status in samples from patients enrolled in the CO.17 trial that 
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randomized fluoropyrimidine-, irinotecan- and oxaliplatin-refractory mCRC patients 
to cetuximab or BSC. The anti-EGFR antibody significantly improved PFS (3.7 
months vs. 1.9 months, HR 0.40, p<0.001) and OS (9.5 months vs. 4.8 months, HR 
0.55, p<0.001) only among patients with KRAS wild-type tumors75. As a result of the 
above reported results, demonstrating the negative predictive value of KRAS codon 
12 and 13 mutations, the use of cetuximab is now restricted to patients with KRAS 
wild-type disease78. 
Unfortunately, although the specificity of KRAS testing as predictor of 
resistance to anti-EGFR monoclonal antibodies is quite high, the sensitivity is less 
satisfactory79, so that while patients bearing such alterations do not benefit from 
treatment, a percentage of patients with KRAS wild-type status does not achieve 
benefit from anti-EGFR antibodies. Additional predictive biomarkers are therefore 
eagerly awaited in order to refine molecular selection for anti-EGFR treatment 
allocation.    
KRAS activating mutations, occurring in codons other than 12 and 13, have 
been described in mCRC. Codon 61 and 146 mutations80 determine the constitutive 
activation of RAS protein, by reducing its intrinsic GTPase activity or increasing its 
affinity for GTP. It has been recently reported that, among 87 patients with KRAS 
codon 12 and 13 wild-type disease, none of the patients bearing codon 61 or 146 
mutations responded to cetuximab plus irinotecan, compared to 22 out of 68 wild-
type patients (p=0.096) and KRAS rarer mutations were also associated with shorter 
PFS (HR 0.46, p=0.028)81. More recently, a European retrospective study82 over 
1022 samples of cetuximab-treated patients showed that codon 61 mutations (but not 
codon 146 mutations) had an adverse effect similar to codon 12 mutations: in fact, 
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patients harbouring codon 61 mutant tumors had a significantly lower RR than did 
patients with wild-type disease (0% vs. 35.7%, p=0.0055), but this difference was not 
observed among patients with codon 146 mutant tumors (18.2% vs. 36.9%, p=0.34). 
Moreover, authors found that codon 146 mutations co-occurred with other KRAS 
mutations, suggesting that this might not be an important oncogenic site. Moreover, 
in a large retrospective pooled exploratory analysis of chemotherapy-refractory 
patients83, a positive association between KRAS G13D mutations and cetuximab 
treatment was seen in regard to better OS and PFS: compared to patients with other 
KRAS-mutated tumors, the 32 patients with G13D-mutated tumors treated with 
cetuximab had longer median OS (7.6 vs. 5.7 months; HR 0.50, 95%CI 0.31-0.81, 
p=0.005) and longer median PFS (4.0 vs. 1.9 months; HR 0.51, 95%CI 0.32-0.81, 
p=0.004). There was a significant interaction between KRAS mutation status (G13D 
vs. other KRAS mutations) and OS benefit with cetuximab treatment (HR 0.30, 
95%CI 0.14-0.67, p=0.003). Tejpar et al. have recently presented data regarding 
G13D mutation for first-line OPUS and CRYSTAL trials: heterogeneous treatment 
effects were seen for all endpoints across the mutation types with significant 
treatment interaction by KRAS mutation status for RR, PFS and OS and among the 
83 patients harbouring a G13D mutant tumor the addition of cetuximab improved the 
activity and the efficacy of chemotherapy, even though to a lesser extent, compared 
to wild-type patients84. However, other confirmatory results from prospective 
randomised trials are needed before definitive conclusions about the predictive role 
of the G13D mutation can be inferred. 
Among the other molecular determinants with already validated usefulness in 
the clinics is BRAF mutational status. BRAF is a member of the RAF gene family 
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(comprising BRAF, ARAF1 and RAF1) which encodes a serine-threonine protein 
kinase that is a downstream effector of activated KRAS. The most frequent (over 
95% of the cases) BRAF mutation is the V600E mutation within the kinase activation 
domain of the B-RAF protein82. Functional consequences of the V600E mutation are 
not completely understood, but it is conceivable that it results in increased MAPK1/3 
activation, as seen for mutant KRAS, since BRAF acts downstream of KRAS to 
activate MAP2K. BRAF mutations occur in about 10-15% of CRC cases85, with 
higher percentages reported in earlier lines of therapy. Interestingly, KRAS and 
BRAF mutations are mutually exclusive in CRC82, suggesting that they could identify 
different tumor subtypes: in fact, BRAF mutant tumors are clinically and 
histologically different from KRAS-mutant ones86. Moreover, from a biological 
perspective BRAF mutations are associated with the CpG island methylator 
phenotype (CIMP) and microsatellite instability, whereas KRAS mutations are more 
common in CIMP-low and microsatellite-stable tumors86. Nowadays V600E-mutant 
BRAF is recognized as probably the most important negative prognostic determinant 
in mCRC, while the prognostic role of KRAS mutations (beyond their proved 
predictive effect for anti-EGFR agents) has not been convincingly demonstrated85. 
All retrospective and post-hoc analyses of BRAF mutations in mCRC series clearly 
showed that the prognosis of mutant tumor is worse than that of wild-type cases. 
Even in the first-line setting, the CRYSTAL trial reported poor PFS and OS results 
among patients with BRAF mutant tumor both in the control (5.6 and 10.3 months, 
respectively) and experimental arm (8.0 and 14.1 months, respectively)52. 
On the other hand, great debate is ongoing about the additional predictive role 
of BRAF V600E mutation in KRAS wild-type mCRC patients receiving anti-EGFR 
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agents. In most studies, no response was seen with the use of cetuximab or 
panitumumab in patients with BRAF mutant mCRC in the chemotherapy refractory 
setting81,82,87,88,89 and the available data strongly suggest that this mutation confers 
resistance to anti-EGFR monoclonal antibodies. Among previously untreated 
patients enrolled onto the CRYSTAL study, the results are limited but the small 
sample size prevents any conclusion: however, no clear benefit in terms of RR 
(15.2% vs. 19.2%, p=0.91) and only a modest gain in efficacy (median PFS: 5.6 vs. 
8.0 months; HR 0.934, 95%CI 0.425-2.056, p=0.87) from the addition of cetuximab 
to chemotherapy were evident at subgroup analysis52.   
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CHAPTER 2. CANCER STEM CELLS: ESSENTIALS OF BIOLOGY 
 
 
 
1.1. Cancer stem cells and colorectal cancer 
 
The classical model of cancer development and progression (i.e. the stochastic 
model) holds that most or all cancer cells have inherent tumorigenic potential and 
have the same possibility to develop oncogenic mutations: in such a model, tumor 
heterogeneity is caused by subclones of tumor cells that result from a combination of 
different microenvironments and random genetic changes90. 
In the last few years an alternative approach to cancer modelling (the so called 
cancer stem cell [CSC] model) has been proposed and is now supported by growing 
evidences90. Stem cells are defined as cells that have two key properties, i.e. the 
ability to perpetuate themselves (or self-renewal) and to generate all the 
differentiated cells of the tissue of origin through differentiation (multipotency)91. 
Self-renewal is the result of asymmetric division, which generates a quiescent stem 
cell (with extensive proliferative capacity and the same developmental potential as 
its parent) and a committed progenitor. Normal stem cells and CSCs share similar 
signalling pathways (such as Wnt, Sonic Hedgehog and Notch) and epigenetic 
modulators (such as Polycomb genes) for regulation of self-renewal92. According to 
the CSC model, human malignancies are hierarchically organized, with CSCs at the 
apex, because they are the only cancer-initiating cells within a tumor. CSCs display 
three essential characteristics93: 1) the expression of a repertoire of markers common 
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to stem and progenitor cells; 2) unlimited growth in vitro using media optimized for 
normal stem cell cultures; 3) ability to reproduce the parental tumor upon injection in 
immunocompromised mice. Through asymmetric division, CSCs generate also non-
self-renewing cells that finally give rise to tumor heterogeneity. Importantly, the 
stochastic model and the CSC model should not be seen as mutually exclusive90. In 
fact, CSCs (as other malignant cells) likely exhibit genomic instability and in the 
course of tumor progression different subclones of CSCs may develop: these distinct 
subsets may then give rise to genomically distinct non-tumorigenic cells. 
Intriguingly, CSCs may arise from normal tissue stem cells, but recent studies 
suggest that they can also develop from progenitor cells, i.e. non self-renewing cells 
that acquire the capacity for self-renewal90. 
Models of carcinogenesis have not only theoretical implications, but also 
relevant practical significance. According to the stochastic model, effective treatment 
of cancer must involve eradication of all cancer cells, since all cancer cells are 
tumorigenic. On the contrary, if we interpret cancer as a CSC-driven disease, 
effective treatment modalities will be based on direct targeting of CSCs, rather than 
non-tumorigenic cells, which can not further sustain cancer growth90. Moreover, 
since CSCs represent only a small fraction of the tumor mass, it is conceivable that 
objective response, as evaluated by conventional radiological imaging may be not the 
best way to evaluate strategies targeting the CSC compartment94. Finally, the CSC 
model prompts us to rethink the way we investigate the mechanisms of resistance to 
anticancer treatments and we identify potential predictive factors through 
pharmacogenomic analyses: indeed one possible pitfall of these studies could reside 
in the underestimation of the contribution of CSCs to drug response95. 
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Even though the CSC model may not apply to all cancer types, recent literature 
data provide reliable evidence that cells with stem cell properties may be identified 
in most of solid malignancies90,92. As regards CRC, convincing experimental 
evidence supporting the existence of colonic CSCs has been recently provided96,97. 
Several authors have independently demonstrated that the CRC tumorigenic cell 
population can be isolated by means of the expression of different cell surface 
biomarkers: such experiments used flow cytometric analysis and spheroid culture 
formation to identify cells through specific surface markers that might enrich for the 
tumorigenic stem cell compartment of the tumor mass. Most of these studies used 
CD133 to identify a colon cancer-initiating cell population in human tumors98,99, but 
a plethora of putative CSC markers have been proposed (Table 2.1). CD133, also 
known as prominin-1, is structured as a five transmembrane domain molecule and is 
located in the apical plasma membrane protrusions of embryonic epithelial 
structures100: despite some intriguing hypothesis suggesting a role in the regulation 
of plasma membrane structure and function, the exact role of CD133 remains 
unknown. CD133+ cells account for approximately 2.5% of the bulk tumor cells and 
do not express the cytokeratin (CK) 20 epithelial marker (which identifies terminally 
differentiated cells), while they express the epithelial adhesion molecule BerEp4 
(also known as EpCAM)98,99. In clonogenic assays, cultured CD133+ cells are 
capable of colonies and crypt-like structures formation. When cultured in serum-free 
liquid medium, they organize in spheres which can be transplanted into 
immunosuppressed non-obese diabetic/severe combined immunodeficiency 
(NOD/SCID) mice resulting in tumor formation, whereas the CD133− cell population 
was unable to generate tumors98,99. Some authors calculated that the frequency of 
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CRC-initiating cells in an unfractionated population of cancer cells is approximately 
one out of 5.7×104: however, when enriched for CD133+ cells, frequency rises up to 
one out of 262 cells96. Further supporting the existence of a real CSC population in 
CRC, tumor xenografts generated by CD133+ cells have the same morphologic 
features of the parental tumor (with CD133+ and CD133− cells present at similar 
ratios to the original tumor) and can be maintained upon serial transplantation. Since 
CD133 is expressed at lower frequency also in the normal colonic tissue, it can be 
hypothesized that CSCs in CRC arise from malignant transformation of normal 
colonic stem cells96,97. Some argued against the role of CD133 as optimal marker for 
CSC identification, since CD133 mRNA and protein are expressed by both 
differentiated cancer cells and CSCs in CRC specimens101. Methodological issues 
should however be taken into account, since it has been recently shown that only one 
CD133 epitope (AC133) is specifically expressed by CSCs due to differential 
glycosilation of the protein102.  
Alternatively, other groups employed additional (or alternative) markers for 
CSCs isolation from CRC samples. Dalerba et al.103 proved that, as previously seen 
for CD133+ cells, cells expressing both CD44 (which acts as a receptor for the 
extracellular matrix component hyaluronan, thus regulating cell survival, motility 
and chemoresistance) and EpCAM (i.e. CD44+/EpCAMhigh) resulted in the 
generation of tumor xenograft with high frequency when injected subcutaneously 
into NOD/SCID mice, whereas CD44−/EpCAMlow cells lack tumor-initiating 
activity. Further subfractionation of the CD44+/EpCAMhigh cell population has been 
attempted by using the mesenchymal stem cell marker CD166: the tumorigenic 
potential of the CD44+/EpCAMhigh/CD166+ (as measured by xenograft formation) 
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increased, suggesting that a combination of markers might be a more reliable 
indication of stemness than CD133 alone. However, even with the use of these 
apparently more robust markers uncertainties exist, since CD44 expression may be 
demonstrated by immunohistochemistry not only in the stem cell compartment at the 
crypt bottom but also in cells within the proliferative compartment of normal colonic 
epithelium96.  
More recently, aldehyde dehydrogenase 1 (ALDH1) has been proposed as a 
promising new marker for both normal and malignant human colonic stem cells104. 
Flow cytometric isolation of cancer cells based on enzymatic activity of ALDH1 and 
subsequent injection into NOD/SCID mice not only resulted in the formation 
xenograft tumors, but also proved highly effective in generating cancer (since as few 
as 25 cells were sufficient) in animals. Interestingly, further refinement of CSC 
isolation by the use of a second marker (CD44+ or CD133+ serially) only modestly 
increased enrichment based on tumor-initiating ability. Thus, in the experience by 
Huang et al. ALDH1 seems to be a specific marker for identifying, isolating, and 
tracking human colonic stem cells during CRC development.  
 
 
1.2. Preliminary clinical implications of the cancer stem cell hypothesis in 
colorectal cancer 
 
Intriguing despite somewhat conflicting results in colorectal CSC isolation 
have prompted the way toward the investigation of clinical implications of CSC 
markers in patient with CRC. Results are still limited, but available preliminary 
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experiences are moving faster the translation of CSC concepts in the medical 
practice.  
Horst and colleagues105 first evaluated CD133 expression by 
immunohistochemistry in 77 CRC specimens selected as moderately differentiated 
T2 or T3 N0 M0 tumors. As previously shown, author confirmed that the CD133 
antigen is localised on the glandular-luminal surface of CRC cells, expression being 
confined to the apical luminal surface of CRC cells with glandular differentiation, 
whereas undifferentiated tumor cells at the front of invasion (the so called tumor 
“buds”) are generally CD133−. Moreover, in this series CD133 levels were 
independently associated with prognosis: in fact, CD133high tumors (i.e. showing 
more than 50% positive glands) were associated with a significantly lower 5-year 
and 10-year OS compared to tumors showing CD133low expression. In line with 
these data, Li et al.106 reported a lower 5-year OS survival rate among patients with a 
higher percentage of CD133+ cells (≥5%) than in those with a lower percentage of 
CD133+ cells in a series of 104 stage IIIB CRC cases. Artells et al.107 assessed 
CD133 expression measuring mRNA levels by real-time quantitative polymerase 
chain reaction (RT-PCR) in tumor and matched normal tissue from 64 CRC patients 
with radically resected stage I–III disease, and correlated tumor CD133 levels with 
clinical and pathological characteristics and clinical outcome. Among the 60 patients 
with detectable CD133 mRNA, expression levels were significantly higher in tumor 
than in normal tissue and higher levels of CD133 expression were associated with 
shorter relapse-free interval (RFI) and OS, and prognostic significance of CD133 
levels was retained also at multivariate analyses. Similar association with risk of 
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recurrence were achieved measuring CD133 mRNA levels in peripheral blood 
samples of another series of 66 colon cancer patients with stage I-IV disease108.  
As previously discussed in this chapter, CD133 may be not the optimal 
markers for colorectal CSC isolation. Interestingly, Saigusa et al.109 evaluated OCT4 
and SOX2 (which are putative markers of stem cells) together with CD133 by RT-
PCR and immunohistochemistry among 33 patients with rectal cancer undergoing 
preoperative chemoradiation and found that higher levels of the three studied genes 
were associated with poorer disease-free survival (DFS). Lugli et al.110 reported the 
results of a tissue microarray of 1420 primary CRC cases and 57 normal mucosa 
samples analyzed by immunohistochemistry for protein markers CD133, CD44, 
CD166, EpCAM, and ALDH1: differences between normal tissue and cancer were 
observed for all markers and, intriguingly, loss of membranous CD166 and CD44 
was associated with higher pathological T and N stage, an infiltrating growth pattern 
and worse OS in univariate analysis only. Due to their role as adhesion molecules, 
authors tested the hypothesis that CD44 and CD166 loss might result in higher 
invasive potential of tumor cells in vitro: for all the three cell lines evaluated, 
CD44−/CD166− cells exhibited significantly higher invasive potential than the 
CD44+/CD166+ counterparts. 
Probably, the most interesting study evaluating the prognostic value of CSC 
markers among colon cancer patients is the one recently published by Iinuma and 
colleagues111. Authors measured by RT-PCR the expression of CEA, CK19, CK20, 
and CD133 mRNA from blood samples (collected before surgery) of 735 CRC 
patients: after initial testing in a 420 patient-cohort, validation was achieved in the 
remaining 315 cases. The expression of CEA/CK/CD133 was associated with 
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significantly poorer DFS and OS in Dukes’ B and C stage CRC cases, and this 
prognostic value was retained also at multivariate analysis. 
As seen for CSC markers, no consensus exist about the optimal methods for 
CSC detection in the real clinical scenario: therefore, results of these preliminary 
experiences are limited by differences in the techniques used for CSC detection and 
cut-off values for patient stratification112,113. Moreover, data interpretation is made 
difficult by the small sample size of the published series, which prevents any 
definitive conclusion about the usefulness of CSC markers in the clinics112. Future 
studies exploring different methods on larger series will help to clarify definitively 
the prognostic implications of colorectal CSCs.  
 
 
1.3. Epigenetics and cancer stem cells: role of Polycomb Repressor Complexes 
 
The study of epigenetic (i.e. DNA sequence-external) modifications has 
recently gained increasing importance in the study of cancer biology, being moved 
forward by the rapidly evolving field of CSCs in solid malignancies. Epigenetic 
alterations are represented by losses (or gains) of DNA methylation and deviant 
patterns of histone modifications: DNA methylation and histone modifications are 
recognized mechanisms that can influence DNA accessibility, which is essential for 
DNA repair, DNA replication, and gene transcription114,115.  
Since epigenetics is a key regulator of multiple cellular processes, including 
the balance between self-renewal and differentiation in both embryonic and adult 
stem cells, it is conceivable that epigenetic modifications play a crucial role in CSC 
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behaviour92. Moreover, recent evidences suggest that CSC mechanisms of resistance 
to cytotoxic agents may be at least in part based on epigenetic gene regulation of 
DNA repair, apoptosis and cell-cycle control116, thus opening the way toward 
therapeutic reversal of epigenetic modifications as a potential resensitizing strategy 
to conventional agents. 
In comparison to gene mutations, which have been classically recognized as 
the key event in cancer development, activation or inactivation of specific genomic 
regions through epigenetic chromatin state modifications confers plasticity to stem 
cells, an essential property for maintenance of tissue homeostasis through 
multipotency117. Moreover, if the contribution of genetic alterations to malignancy is 
well understood, a model of carcinogenesis based only on genetic abnormalities can 
not account for the potential deleterious effects of a high mutation rate (for example, 
the trigger of apoptosis in highly mutated cells)118 or for the lack of identifiable 
mutations in classical progression-related genes in some tumors119. Feinberg et al. 
have recently proposed an epigenetic progenitor model of human cancer, in which 
CSCs might originate from early epigenetic events (or epimutations) occurring in 
normal tissue stem cells, transit-amplifying cells or bone marrow-derived cells119. 
Epigenetic modifications thus offer a useful instrument to explain tumor 
heterogeneity compared with the simplified model of sequential mutational events.  
In line with this model, epigenetic modifiers have been proved essential for 
stem cell biology. Polycomb group (PcG) genes probably represent the most studied 
and well-known epigenetic effectors in CSCs. First discovered for its role in 
Drosophila development, PcG are a highly evolutionarily conserved gene family, 
which encode for a group of epigenetic silencers, mainly organized in two 
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functionally and biochemically distinct multiprotein complexes, called Polycomb 
repressive complexes (PRCs) 1 and 2 (PRC1 and PRC2)120,121. PRC2 is involved in 
gene silencing initiation, through methylation of histone H3 lysine 9 and 27, and 
histone H1 lysine 26, all of which are markers of inactive chromatin. PRC2 
comprises several components, including the core components enhancer of zeste 1 
and 2 (EZH1 and EZH2), suppressor of zeste-12 (SUZ12), and embryonic ectoderm 
development (EED). SUZ12 and EED are required for complex stability and for the 
methyltransferase activity of the EZH2, which mediate histone H3 lysine 27 
trimethylation (denoted as H3K27me3)122. PRC1 binds to H3K27me3 and 
definitively complete gene silencing through ubiquitination of lysine 119 of histone 
H2A (denoted as H2AK119ub). As PCR2, also PCR1 consists of several proteins 
including CBX2 (chromobox homolog 2) or related homologs (responsible for 
binding to H3K27me3), RING1A (ring finger protein 1A) or RING1B (which 
catalyse ubiquitination) and BMI1 (B-cell-specific Moloney murine leukemia virus 
integration site 1) or PCGF2 (polycomb group ring finger 6/Mel18), which are 
involved in the regulation of the ubiquitination activity120. These epigenetic 
modifications regulate gene transcription by creating an obstacle to transcription 
factor and RNA polymerase binding and by recruiting DNA methyltransferases 
(DNMT) (DNMT1, DNMT3A and DNMT3B)123,124.  
BMI1 and EZH2 are the two main actors in normal stem cells and CSCs 
epigenetics. As regards BMI1, this central role in stem cell behaviour is mainly 
mediated through several key pathways, including anchorage-independent growth, 
Wnt and Notch signalling95. On the other hand, EZH2 is required for E-cadherin 
silencing, which represents an essential step in the development of an invasive 
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phenotype in epithelial tumors125. Focusing on the role of EZH2 in cancer 
development and progression, initial evidences of a strict link between this key 
epigenetic effector and malignancy were derived from microarray studies in prostate 
and breast cancer, and were subsequently confirmed in other tumor types126: in these 
series, EZH2 overexpression has been generally associated with increased tumor 
aggressiveness, which appears in line with in vitro studies proving the oncogenic 
potential of EZH2 by induction of anchorage-independent colony growth and 
invasion126. Moreover, since an intimate link exist between DNMTs and EZH2, 
PRC2 might be involved in aberrant methylation of CpG islands at specific gene 
promoters, a distinctive feature frequently found in many cancers, as demonstrated 
by the concomitant presence of aberrant CpG island methylation and enrichment of 
PRC2 and H3K27 methylation127,128. 
EZH2 overexpression may be triggered by deletions of microRNA-101, which 
is a negative regulator of EZH2 expression, as described in prostate cancer129. More 
recently, acquired EZH2 mutations resulting in gain of function in EZH2 activity 
have been identified in haematological malignancies. In particular, different 
heterozygous mutations at amino acid Y641 within the SET domain have been found 
in 7% of follicular lymphomas and 22% of diffuse large cell B-cell lymphomas of 
germinal centre origin130. While normal EZH2 mediates the first methylation 
reaction of histone H3K27 more efficiently than the subsequent mono- to di- and di- 
to trimethylation reactions, the Y641 mutants display opposite properties131: thus, 
heterozygous Y461 mutants cooperate with wild-type EZH2 to increase levels of 
H3K27me3. 
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Intriguingly, EZH2 have been recently involved also in the regulation of tumor 
angiogenesis132. Lu et al. have recently published their results showing that EZH2 
expression in either tumor cells or tumor vasculature is associated with higher tumor 
stage and grade and is predictive of poor clinical outcome in a series of 180 epithelial 
ovarian cancers. Moreover, higher EZH2 expression in the vasculature was 
associated with greater microvessel density. VEGF was shown to induce EZH2 
expression through a paracrine circuit: in turn, EZH2 methylates and silences 
vasohibin1 (vash1), an antiangiogenic gene. EZH2 silencing in the tumor-associated 
endothelial cells resulted in inhibition of angiogenesis through the increase in vash1 
transcription: this action reduced ovarian cancer growth, a result which is further 
enhanced when EZH2 is silenced in tumor cells too. Therefore, EZH2 may represent 
an intriguing target for novel anticancer agents not only for its direct effect on the 
regulation CSC behaviour, but also for its indirect effect on tumor growth through 
regulation of angiogenesis.  
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Table 2.1. Markers of normal intestinal stem cells and colorectal CSCs 
 
 
 Marker Function Reference 
Normal intestinal stem cells Musashi-1 RNA-binding protein 96, 97 
 Hes-1 Transcriptional repressor 96, 97 
 EphB receptors Cell surface receptors 96, 97 
 BMI1 Policomb-repressor protein 96, 97 
 Lgr5 Unknown, WNT target gene 96, 97 
 Aldh1 Enzyme 96, 97 
Colorectal CSCs CD133 Unknown 98, 99 
 CD44 Hyaluronic acid receptor 103 
 CD166 Adhesion molecule 103 
 Aldh-1 Enzyme 104 
 
 
Abbreviations: CSCs, cancer stem cells.  
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Figure 2.1. Simplified view of PcG function 
 
    
       
 
 
Polycomb repressive complex 2 (PRC2) catalyzes histone H3 lysine 27 (H3K27) 
trimethylation, resulting in the recruitment of Polycomb repressive complex 1 
(PRC1), which in turns ubiquitinates lysine 119 of histone H2A (H2K119), DNA 
methyltransferase (DNMT) and histone deacetylase (HDAC): these changes finally 
lead to chromatin compaction and transcriptional repression [modified from ref. 
126].
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CHAPTER 3. EZH2 POLYMORPHISMS AND OUTCOME OF METASTATIC 
COLORECTAL CANCER PATIENTS 
 
 
 
3.1. Rationale 
 
As previously discussed, mCRC is one of the most frequent malignancies and 
one of the leading causes of cancer death in Western countries1,2. The therapeutic 
armamentarium against mCRC has rapidly increased in the last decade4,7: for the 
majority of mCRC patients, doublet chemotherapy with a fluoropyrimidine plus 
either irinotecan or oxaliplatin combined with a biologic agent is nowadays 
considered the preferred treatment option in first-line7. In particular bevacizumab, a 
fully humanized monoclonal antibody directed against the VEGF, proved to improve 
the efficacy of chemotherapy alone in several phase III trials with different 
regimens43,44,45 and is approved in combination with fluoropyrimidine-based 
chemotherapy for the first- or second-line treatment of mCRC patientsa.  
Despite these profound changes, long-term prognosis remains unfavourable, 
median OS not exceeding 24 months even in most recent studies7. Results from 
clinical trials and everyday practice clearly show that among mCRC patients, 
outcome widely vary according to several factors. Up to now, reliable prognostic 
parameters are represented by basal clinical and laboratory variables, validated 
                                                
a http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s01691bl.pdf 
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among thousands of mCRC patients often treated with older chemotherapy 
regimens133.  
With the few promising aforementioned exceptions63, validated molecular 
markers of disease course are still lacking. In addition, genetic variants of drug 
targets or drug-metabolizing enzymes have been extensively tested as putative 
predictors of benefit from therapy: this has led to intriguing but often conflicting 
results among different series, making the aim of personalized medicine a 
challenge134,135. 
Recent evidence indicates that CRC is a stem cell-driven disease. Colorectal 
CSCs, mainly identified based on the CD133 surface marker expression, account for 
a minority (less than 3%) of the total tumor mass98. They share with normal stem 
cells the two key properties of stemness: the ability to self-renew and to differentiate 
into many cell types. In addition, colorectal CSCs display a unique tumorigenic 
potential98, are more resistant to 5-fluorouracil-based chemotherapy136 and more 
invasive than the other tumor cells137. For these reasons, CSCs are thought to be the 
seeds of tumor initiation, therapy resistance and metastatic spreading138. Thus, the 
identification of molecular markers based on CSCs activity could provide innovative 
tools to stratify mCRC patients, optimize treatment choices and identify new 
therapeutic targets.  
PcGs are epigenetic effectors essential for stem cell self-renewal and lineage-
specific gene silencing116. During development, they orchestrate tissue specification 
and body plan segmentation. PcGs are organized in multimeric Polycomb repressive 
complexes (PRCs), named PRC1-4. In addition to its role in stem cell biology and 
development, PRC2 is crucial for CSC self-renewal and tumor progression116. It is 
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made up by 4 proteins, and is able to bind specific DNA sequences to catalyze 
histone H3 lysine 27 trimethylation116. This epigenetic mark triggers gene silencing. 
EZH2 is the catalytic subunit of PRC2. It is essential for CSC self-renewal in several 
solid tumors116,117, where it mediates E-cadherin silencing and cancer cell 
invasion125. In addition, pharmacological inhibition of EZH2 induces apoptosis in 
CRC cell lines, by up-regulating the apoptosis effector FBXO32139. 
Immunohistochemical analyses revealed that EZH2 is an independent prognostic 
indicator in CRC, and that its expression significantly increases with tumor stage140. 
In addition, high EZH2 mRNA expression predicts shorter OS in CRC patients141. 
Due to its role in CSC biology and CRC progression, EZH2 is an interesting 
candidate as a novel prognostic marker. 
Single nucleotide polymorphisms (SNPs) have been long tested as prognostic 
and predictive biomarkers, since they are easy-to-detect genetic variants that can be 
analyzed from a peripheral blood sample. Thus, they are attractive molecular 
markers for translational studies. Recently, the EZH2 locus has been mapped for the 
presence of SNPs in normal individuals and lung cancer patients142. Three EZH2 
SNPs were shown to predict lung cancer risk, while another was characterized as 
producing an aminoacidic change in the EZH2 protein.  
Moving from the hypothesis that polymorphic variants of such a key 
determinant of CSCs biology may affect clinical outcome, we aimed at investigating 
the role of these four EZH2 SNPs among mCRC patients treated with a modern first-
line regimen such as FOLFIRI with or without bevacizumab.  
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3.2. Materials and methods 
 
3.2.1. Oncomine analysis 
 
Oncomine 4.4 database143 collects gene expression data from cancer patients. 
This database was interrogated to investigate significant overlaps between two 
concepts: “Activated upon Polycomb Group knockdown”144 and “Patient Treatment 
Response” in CRC. We found just two significant overlaps (p<0.01, Odds Ratio 
>2.0): one relative to gene expression changes after exposure to 5-FU in rectal cancer 
(Clarke-Colon data set), and one relative to response to FOLFIRI regimen in mCRC 
patients (Graudens-Colon data set). In the latter case, gene expression analysis was 
performed on primary tumors and metastasis of chemotherapy-naïve patients. All 
patients were treated with the FOLFIRI regimen, and responders and non-responders 
were classified according to the World Health Organization (WHO) criteria.  
We aimed at investigating mCRC patients treated with a currently employed 
chemotherapy regimen: we therefore focused on the latter data set.  
Since EZH2 expression was not reported in Graudens-Colon, we identified two 
studies on stage II-III CRC patients treated with fluoropyrimidine-based 
chemotherapy (Jorissen Colorectal 3, and Smith Colorectal), which reported EZH2 
expression.  
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3.2.2. Patient selection and study treatment  
 
We retrospectively identified patients with histologically confirmed, metastatic 
colorectal adenocarcinoma receiving first-line FOLFIRI with or without 
bevacizumab. Different schedules of the FOLFIRI regimen were allowed, either: 
- irinotecan 180 mg/sqm intravenously on day 1; 
- LV 200 mg/sqm intravenously on day 1; 
- 5-FU 400 mg/sqm bolus intravenously on day 1, followed by 5-FU 
2400 mg/sqm 46-hours continuous infusion (ci) intravenously on days 1 to 
3; 
or:  
- irinotecan 180 mg/sqm intravenously on day 1; 
- LV 200 mg/sqm intravenously on day 1; 
- 5-FU 3200 mg/sqm 48-hours ci intravenously on days 1 to 3 (without 
bolus administration). 
Bevacizumab was administered at the dose of 5 mg/kg intravenously over 30 
minutes on day 1. Each cycle was repeated every 2 weeks.  
Patients were considered eligible for inclusion into the study if they had 
received an actual dose intensity of 5-FU and irinotecan of at least 85% of the 
projected dose intensity. 
Pretreatment evaluation included medical history, physical examination and 
assessment of performance status. Complete blood cell count with differential, 
routine chemistry, liver and kidney function tests, CEA analysis and a computed 
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tomography scan of the chest and abdomen were performed before treatment start 
and every 2 months until evidence of disease progression.  
 
 
3.2.3. Evaluation of activity and efficacy 
 
Objective response assessment was performed according to Response 
Evaluation Criteria In Solid Tumors version 1.1 (RECIST)145. The assessment of 
response and progression was based on investigator-reported measurements. All 
patients with measurable lesions were evaluated for response, while all genotyped 
patients were included in the PFS and OS analyses. PFS was defined as the time 
from the date of treatment start until the evidence of disease progression or death 
from any cause, whichever occurred first. Patients who underwent secondary radical 
surgery on metastases were censored at the time of surgery. OS was defined as the 
time from the date of treatment start until death from any cause. 
 
 
3.2.4. Sample collection, DNA and RNA isolation 
 
Peripheral venous blood samples from an antecubital vein of 110 mCRC 
patients treated with first-line FOLFIRI plus bevacizumab were collected before 
treatment start and stored in anonymity at -20°C in the laboratory of Pharmacology 
(Department of Internal Medicine, University of Pisa, Italy) until molecular analyses 
were performed. DNA analyses were performed by investigators who were blinded 
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to clinical data. Patients provided written informed consent before entering the study. 
The study was conducted in accordance to the Declaration of Helsinki and to the 
Good Clinical Practice guidelines and protocol was approved by the Ethics 
Committee of Pisa University Hospital. Patients were informed of the investigational 
nature of the study and provided their written informed consent before registration 
onto the study. 
Genomic DNA was isolated using the QIAamp DNA mini kit (Qiagen). The 
purity and quantity of DNA obtained, was measured by Uvikon-940 
spectrophotometer (Kontron). A volume of 1 µl of DNA was diluted in 499 µl of 
autoclaved DNase-RNase-free water. DNA Absorbance was read at 260 nm, whereas 
protein contamination was assessed by the 260/280 nm absorbance ratio. 
Both DNA and RNA were extracted from peripheral blood lymphocytes of 50 
consecutive radically resected stage II or III CRC patients, as previously 
described146. Blood samples were collected before the start of adjuvant treatment. 
RNA was retro-transcribed, as described in previous report146. 
 
 
3.2.5. SNP genotyping and EZH2 mRNA expression 
 
EZH2 SNPs [c.553G>C (rs2302427); c.2110+6A>C (rs41277434); c.626-
394C>T (rs3757441); g.91772121T>C (rs6958683)] were analyzed through Real-
Time PCR. SNPs of our interest were studied with TaqMan probe–based assays 
using the PCR Real-Time ABI PRISM 7900HT instrument equipped with the 
Sequence Detection System version 2.0 software (Applied Biosystems). Assays IDs 
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were: C__15757626_10 (rs2302427) and C___326857_10 (rs3757441). The 
remaining SNP assays have been designed through File-Builder software (Applied 
Biosystems). The PCR reactions were done using 20 ng of genomic DNA diluted in 
11.875 µl DNase-RNase–free water, 12.5 µl of TaqMan Universal PCR Master Mix 
with AmpliTaq Gold, and 0.625 µl of the assay mix (forward and reverse specific 
primers and the specific probes), in a total volume of 25 µl. Applied Biosystems SNP 
genotyping assays were used for genotyping. The allelic content of each sample in 
the plate was determined by reading the generated fluorescence. 
After retro-transcription, cDNA from a parallel cohort of 50 CRC patients was 
used to measure EZH2 expression, using glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as reference gene. Applied Biosystems gene expression assay numbers 
were: 4326317 (GAPDH) and Hs01016789_m1* (EZH2). Figure 2 shows -ΔCt 
values, normalized to the lowest EZH2 expression level.  
 
 
3.2.6. Statistical analysis 
 
This retrospective analysis aimed to evaluate the relation of EZH2 
polymorphisms with outcome parameters such as: 
- response rate (RR); 
- PFS; 
- OS.  
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All polymorphisms were examined for deviation from Hardy-Weinberg 
equilibrium147 by comparing actual allelic distributions with those expected using a 
chi-square test.  
A two-tailed Fisher’s exact test was used to evaluate the association of 
investigated EZH2 SNPs with objective response. PFS and OS were determined 
using the Kaplan-Meier method and compared according to EZH2 SNPs variants 
using the log-rank test. Statistical significance was set at p<0.05 for a two-tailed test. 
Statistical analyses were done using GraphPad Prism (version 5) software. 
We used a Cox model to evaluate the effect of 626-394C>T and prognostic 
factors on PFS and OS, using the survival library of the R packageb. For PFS, the 
following factors were considered:  
- age;  
- previous adjuvant chemotherapy;  
- CEA value >100 ng/mL; 
- mucinous histology; 
- timing of metastases; 
- Köhne score.  
For OS, the following factors were included in the analysis:  
- gender; 
- age; 
- timing of metastases; 
- Köhne score; 
                                                
b Terry Therneau and original R port by Thomas Lumley (2009). Survival: survival 
analysis, including penalized likelihood. R package version 2.35-7. http://CRAN.R-
project.org/package=survival 
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- lactate dehydrogenase (LDH) above the upper limit of normal (ULN); 
- previous adjuvant chemotherapy; 
- mucinous histology; 
- secondary surgery of metastases; 
- primary tumor location. 
 
 
3.2.7. In silico characterization of the 626-394C>T SNP 
 
In order to evaluate transcription factor (TF) binding affinity of the C and T 
allele, we used PROMO 3.0 softwarec. We considered only human factors and 
human binding sites, with a maximum matrix dissimilarity rate of 15. DNA sequence 
was downloaded from “Entrez SNP”d. Using the same DNA sequence (and its 
complementary inverted counterpart) we tested the hypothesis that this SNP may 
affect the creation of a new splice variant in exon 6 and 7. For this purpose, we 
employed the NCBI Aceview Databasee. 
 
 
 
 
 
 
                                                
c http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3 
d http://www.ncbi.nlm.nih.gov/snp 
e http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=human&l=EZH2 
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3.3. Results 
 
 
3.3.1. Polycomb targets are specifically silenced in FOLFIRI non-responders 
 
To investigate the relationship between EZH2 activity and response to 
chemotherapy, we queried Oncomine 4.4 database, which collects microarray data 
from cancer patients143. In particular, we investigated if PcG targets were 
differentially expressed in chemotherapy-sensitive vs. -resistant CRC patients148. 
PcG targets are silenced by EZH2 through histone H3K27 methylation144. 
Interestingly, we found that PcG targets are silenced in FOLFIRI non-responders, 
compared to FOLFIRI responders (p<0.01, Odds 4.6; Figure 3.1). Keeping with this 
evidence, high EZH2 expression predicts shorter recurrence-free survival and 1-year 
survival rate in CRC patients treated with fluoropyrimidine-based chemotherapy 
(p=0.041 on 100 patients, and p=0.036 on 174 patients respectively). 
Thus, EZH2 seems to be more active in FOLFIRI-resistant patients. For this 
reason, we selected mCRC patients treated with the FOLFIRI regimen in 
combination with bevacizumab. 
 
 
3.3.2. Patient characteristics and treatment outcome 
 
One-hundred and ten patients treated with FOLFIRI plus bevacizumab were 
identified. Patient clinical characteristics are listed in Table 3.1. As regards activity 
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in the entire population, 106 patients were evaluable for response (4 patients were 
not evaluable because they had no measurable disease, i.e. peritoneal 
carcinomatosis): complete response was reported in 13 patients (12%) and partial 
response in 55 patients (52%), thus resulting in overall RR of 64%. Twenty-nine 
(27%) patients achieved disease stabilization as best response, while 9 (8%) 
progressed during treatment. Eight (7%) patients underwent secondary radical (R0) 
surgical resection of metastases.  
At a median follow up of 18.9 months, 72 patients experienced disease 
progression (patients not evaluable for RR were included in the PFS analysis since 
they experienced unequivocal disease progression by the appearance of new lesions 
in different organs) and 40 patients have died: median PFS and OS were 9.9 and 23.3 
months, respectively. 
 
 
3.3.3. Genotype information  
 
Genotype frequencies found in our population are reported in Table 3.2.  
All polymorphisms follow Hardy-Weinberg equilibrium. Frequencies for all 
four polymorphisms are comparable with those reported in a previous study on a 
Caucasian population142. 
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3.3.4. Correlation between EZH2 SNPs and outcome 
 
Correlations between EZH2 SNPs, RR and clinical outcome parameters are 
summarized in Table 3.2. No significant association was detected between 
genotypes and RR (p>0.05 for all comparisons). Similarly, 553G>C, 2110+6A>C 
and 9177211T>C variants did not show significant association with clinical outcome. 
As regards 626-394C>T, median PFS achieved by patients carrying the three 
different variants (T/T, T/C and C/C) were 11.2, 10.1, and 8.7 months, respectively 
(p=0.029). These three genotypes did not differ significantly in terms of median OS 
(18.3, 27.9 and 23.8 months, respectively; p=0.148).  
We noticed a similar PFS between T/T and T/C patients (HR=1.158, 95% CI 
0.690-1.945, p=0.578), while a statistically significant difference was reported 
comparing T/T or T/C with C/C patients (HR=0.260, 95% CI 0.097-0.695, p=0.007, 
and HR=0.345, 95% CI 0.134-0.890, p=0.028, respectively). This observation 
prompted us to compare clinical outcome between C/C homozygotes and subjects 
carrying at least one T allele. When compared with patients with at least one T allele, 
C/C homozygotes showed significantly shorter median PFS (11.0 vs. 8.7 months; 
HR=0.269, 95% CI: 0.102-0.706, p=0.008) (Figure 3.2) and OS (23.8 vs. 18.3 
months; HR=0.329, 95% CI: 0.109-0.997, p=0.049) (Figure 3.3).  
To corroborate our hypothesis, we analyzed the 626-394C>T SNP on an 
additional retrospective cohort of 104 mCRC patients treated with the FOLFIRI 
regimen (without bevacizumab). These patients received the same schedules of 
chemotherapy as administered in the FOLFIRI plus bevacizumab cohort and disease 
status was evaluated as specified in the Materials and Methods for the bevacizumab-
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treated group. For the FOLFIRI-receiving group, multivariate analysis for PFS and 
OS was not performed, since only the best objective response achieved and the dates 
of progression and death were collected. As with FOLFIRI plus bevacizumab, also 
with FOLFIRI alone no significant association between EZH2 genotype and 
objective response was found (probably due to the limited sample dimension: in fact, 
RR was 0% in CC patients and 45% in CT/TT patients, p=0.502), while both PFS 
(Figure 3.4) and OS (Figure 3.5) were significantly shorter in C/C patients 
compared to other genotypes (p<0.05 Log-Rank Test). Unfortunately, we found just 
two C/C patients in this group. This small number prevents any conclusive 
confirmation of our findings. 
 
 
3.3.5. Cox model and interaction test 
 
In order to test the hypothesis that the 626-394C>T SNP is an independent 
prognostic factor in our population, we performed a Cox regression including all 
variables known to possibly affect PFS or OS n mCRC patients. At multivariate 
analysis, C/C genotype retained its significant association with worse PFS 
(HR=2.211, 95% CI: 1.057-4.624; p=0.035) (Table 3.3). This difference reflected 
into a significantly shorter OS (HR=2.851, 95% CI: 1.024-7.938; p=0.045) (Table 
3.3). Another factor found to be associated with worse PFS and OS in our series was 
mucinous histology.  
Due to the small number of C/C patients found in each group, we also 
conducted a multivariate analysis including all 214 patients (treated with FOLFIRI 
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with or without bevacizumab). Analysis variables included therapy regimen 
(FOLFIRI with or without bevacizumab) and EZH2 genotype. This analysis included 
a total of 14 C/C patients. As shown in Table 3.4, C/C genotype was an independent 
predictor of both PFS and OS. As expected, FOLFIRI plus bevacizumab regimen 
was associated with a significant survival advantage. We also tested if EZH2 
genotype predicted a benefit from adding bevacizumab to the FOLFIRI regimen 
(genotype-treatment interaction). As shown in Table 3.4, EZH2 genotype was not 
predictive of bevacizumab efficacy (p>0.05 for both PFS and OS).  
 
 
3.3.6. In silico and in vivo characterization of the 626-394C>T polymorphism 
 
The 626-394C>T SNP was reported as an intronic polymorphism, located 
between exons 6 and 7142. Polymorphic variants located in uncoding regions may 
affect gene functions in many ways, including affinity changes in TF binding sites, 
and alteration of specific splice regions. Due to the putative role of this variant in 
mCRC patients, we investigated if the T-C change at this residue may alter TF 
binding or splicing sites in exons 6 and 7. For this purpose, we used PROMO 3.0 
software and NCBI Aceview database. The latter tool revealed that 23 EZH2 splice 
variants have been described. No one of these includes the residue hosting the 626-
394C>T variant. 
We then evaluated TF binding affected by the C-T variant. As shown in Figure 
3.6, the T allele may create a binding site for the XBP1 factor.  
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To confirm our prediction, we measured EZH2 expression in peripheral 
lymphocytes from 50 consecutive CRC patients. We also analyzed the 626-394C>T 
SNP in these patients. As shown in Figure 3.7, the C/C variant was associated with a 
significantly higher EZH2 expression, with respect to C/T and T/T genotypes 
(p<0.05). Interestingly, EZH2 levels were not significantly different between C/T 
and T/T genotypes.   
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Table 3.1. Patient characteristics 
 
Characteristic N % 
No. of patients 110 100% 
Age, years    
Median (range) 63 (35-79) 
Gender   
Male  57 52% 
Female 53 48% 
ECOG Performance Status   
0 101 92% 
1 8 7% 
2 1 1% 
Primary tumor   
Colon  82 75% 
Rectum 28 25% 
Timing of metastases   
Synchronous 61 55% 
Metachronous 49 45% 
No. of involved organs   
1 56 51% 
2 46 42% 
≥3 8 7% 
Previous adjuvant chemotherapy   
Yes 44 40% 
No 66 60% 
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Köhne prognostic group*   
Low risk 56 52% 
Intermediate risk 39 36% 
High risk 12 11% 
 
Abbreviations: No., number; ECOG, Eastern Cooperative Oncology Group. *For 3 
patients Köhne score was not assessable due to missing data. 
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3.2. EZH2 polymorphisms: association with RR, PFS and OS 
 
Genotype No. (%) 
RR 
(%) p 
Median 
PFS 
(months) 
p 
Median 
OS 
(months) 
p 
553G>C        
C/C 96 (87%) 
59 
(61%)  10.2  23.3  
G/C 13 (12%) 
9 
(69%) 0.587 10.4 0.820 25.4 0.893 
G/G 1 (1%) 
NE  undefined  undefined  
2110+6T>G        
A/A 95 (86%) 
60 
(63%)  10.2  23.1  
A/C 13 (12%) 
7 
(54%) 0.469 10.5 0.695 29.6 0.739 
C/C 2 (2%) 
1 
(50%)  undefined  undefined  
9177211T>C        
C/C 74 (67%) 
43 
(58%)  8.7  23.8  
T/C 33 (30%) 
23 
(70%) 0.287 9.5 0.189 21.6 0.314 
T/T 3 (3%) 
2 
(67%)  11.1  18.3  
626-394C>T        
T/T 62 (56%) 
39 
(63%)  11.2  23.8  
T/C 36 (33%) 
22 
(61%) 0.754 10.1 0.029 27.9 0.148 
C/C 12 (11%) 
7 
(58%)  8.7  18.3  
 
Abbreviations: NE, not evaluable. 
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3.3. Multivariate analysis: FOLFIRI plus bevacizumab cohort 
 
 
Progression-free survival 
Factors HR 95% CI p 
Age 0.993 0.969-1.018 0.596 
Adjuvant chemotherapy    
Yes    
No 0.286 0.077-1.055 0.060 
CEA value >100 ng/mL    
No    
Yes 0.760 0.385-1.498 0.427 
Mucinous histology    
No    
Yes 2.492 1.173-5.293 0.018* 
Timing of metastases    
Metachronous    
Synchronous 2.096 0.551-7.980 0.278 
Köhne score    
High    
Intermediate 0.728 0.314-1.689 0.460 
Low 0.752 0.341-1.660 0.481 
626-394C>T    
T/T or T/C    
C/C 2.211 1.057-4.624 0.035* 
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Overall survival 
Factors HR 95% CI p 
Gender    
Female    
Male 1.147 0.476-2.763 0.761 
Age 1.007 0.962-1.054 0.755 
Timing of metastases     
Metachronous    
Synchronous 1.641 0.452-5.958 0.451 
Köhne score     
High    
Intermediate 0.574 0.178-1.851 0.353 
Low 0.610 0.188-1.978 0.410 
LDH level >ULN     
No    
Yes 2.138 0.839-5.450 0.111 
Mucinous histology    
No    
Yes 5.511 2.119-14.334 <0.001* 
Secondary surgery of metastases     
No    
Yes 0.151 0.014-1.655 0.122 
Adjuvant chemotherapy    
Yes    
No 0.444 0.122-1.623 0.220 
Primary tumor site     
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Colon    
Rectum 0.852 0.329-2.207 0.742 
626-394C>T    
T/T or T/C    
C/C 2.851 1.024-7.938 0.045* 
 
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ULN, upper limit of 
normal. 
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Table 3.4. Multivariate analysis: FOLFIRI with or without bevacizumab  
 
 
Factors HR 95% CI p 
Progression-free survival 
626-394C>T    
T/C or T/T    
C/C 5.752 1.358-24.369 0.018* 
Treatment    
FOLFIRI     
FOLFIRI plus bevacizumab 0.401 0.268-0.601 <0.001* 
Genotype-treatment interaction 0.476 0.092-2.478 0.378 
    
Overall survival 
626-394C>T    
C/C    
T/C or T/T 6.091 1.447-25.635 0.014* 
Treatment    
FOLFIRI     
FOLFIRI plus bevacizumab 0.602 0.398-0.910 0.016* 
Genotype-treatment interaction 0.334  0.064 -1.738 0.193 
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Figure 3.1. PcG targets down-regulated in FOLFIRI non-responders 
 
 
 
 
 
For analysis settings, see “Material and Methods”. Using our filters, we found 2 
significant overlaps: one relative to gene expression changes after exposure to 5-FU 
in rectal cancer (Clarke-Colon data set), and one relative to response to FOLFIRI 
regimen in mCRC patients (Graudens-Colon data set). In the latter case, gene 
expression analysis was performed on primary tumors and metastasis of 
chemotherapy-naïve patients. All patients were treated with FOLFIRI regimen. 
Responders and non-responders were classified according to WHO criteria. Since we 
aimed at investigating mCRC patients treated with a currently employed 
chemotherapy regimen, we focused on the latter data set. 
The figure shows that most PcG targets are silenced in FOLFIRI non-responders 
(p<0.01, Oncomine analysis). 
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Figure 3.2. PFS and EZH2 genotype in the FOLFIRI plus bevacizumab cohort 
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Figure 3.3. OS and EZH2 genotype in the FOLFIRI plus bevacizumab cohort 
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Figure 3.4. PFS and EZH2 genotype in the FOLFIRI cohort 
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Figure 3.5. OS and EZH2 genotype in the FOLFIRI cohort 
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Figure 3.6. Characterization of TF binding sites affected by the rs3757441 SNP 
 
 
 
 
Characterization of TF binding sites affected by the rs3757441 SNP. Prediction on 
XBP binding are performed through PROMO3.0 software, as described in “Materials 
and Methods”. In red, XBP consensus sequence. 
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Figure 3.7. EZH2 mRNA levels in resected CRC patients 
 
 
 
 
 
 
Gene expression in lymphocytes is relative to GAPDH levels. *p<0.05 (ANOVA, 
Bonferroni post-test). 
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CHAPTER 4. DISCUSSION AND CONCLUSIONS 
 
 
 
4.1. Discussion 
 
Our analysis shows that the 626-394C>T EZH2 polymorphism is associated 
with shorter PFS and OS in a group of mCRC patients treated with the FOLFIRI 
(with or without bevacizumab) regimen. EZH2 is emerging as a novel oncogene and 
putative therapy target in oncology149. Along with its role in CSC self-renewal (17), 
EZH2 is known to silence several tumor-suppressor genes, including CDH1 (E-
cadherin) and p16INK4A/p14ARF125,150. E-cadherin is an epithelial surface molecule, 
that regulates cell adhesion and cell growth in CRC cells151. In the gastrointestinal 
tract, E-cadherin silencing is the first step for epithelial-to-mesenchymal transition 
and cancer cell invasion152. In addition, E-cadherin down-regulation contributes to 
Wnt pathway activation153, that in turn triggers 5-FU and irinotecan resistance genes 
in CRC cells154. The p16INK4A/p14ARF locus encodes for two cell-cycle inhibitors 
that activate senescence in response to cellular stress150. In CRC, this locus is a 
frequent target of epigenetic silencing155. This phenomenon leads to uncontrolled 
proliferation and resistance to chemotherapy156. Thus, EZH2 may contribute to CRC 
progression and treatment resistance. Keeping with this hypothesis, high EZH2 
expression has been associated with shorter OS and higher stage in CRC 
patients140,141. In particular, Wang et al.140 showed that EZH2 protein expression is 
an independent predictor of poor prognosis in CRC. 
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The 626-394C>T SNP has been previously characterized as an intronic 
polymorphism142. Intronic SNPs may affect gene expression through several 
mechanisms, including changes in TF binding sites157, microRNA target 
sequences158, and splicing variants159. This SNP is not located on the 3’ UTR region, 
thus it does not likely affect microRNA binding. In addition, we found that the 
residue hosting the 626-394C>T variant is not involved in alternative splicing. Thus, 
a mechanism by which this SNP may affect EZH2 expression is through TF binding. 
Our in silico analysis revealed that the T allele may create a binding site for the 
XBP1 factor (Figure 3.6). Patients carrying the C/C genotype have no binding sites 
for this factor. XBP1 is a basic leucin zipper (b-zip) TF160, which is activated by 
cellular stress (i.e. hypoxia, DNA damage). XBP1 dimerizes with other b-zip 
proteins, thereby binding specific DNA sequences. XBP1-containing heterodimers 
may lead to activation and inhibition of different set of genes, depending on the 
cellular context161. For example, in pancreatic cells, XBP1 inhibits Pdx and Mafa 
genes, thereby suppressing insulin production162. XBP1 is expressed by CRC cells, 
and its up-regulation leads to cell death163. Interestingly, DNA damage is known to 
trigger EZH2 down-regulation164. It is conceivable that, in response to cellular stress, 
XPB1 inhibits EZH2 expression in CRC cells. In patients carrying at least one T 
allele, EZH2 expression may be inhibited by XBP1. In C/C homozigotes, EHZ2 
expression could be deregulated, thereby producing more aggressive tumors. 
Keeping with this hypothesis, we found that EZH2 mRNA levels are higher in C/C 
patients, compared to other genotypes (Figure 3.7). The C/T and T/T genotypes did 
not show a significantly different EZH2 expression. Thus, our data suggest that C/C 
homozygous individuals show both poorer prognosis, and higher EZH2 expression. 
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Interestingly, heterozygous genotype was not associated to intermediate EZH2 
expression and prognosis. Several regulatory mechanisms may account for the same 
expression levels in C/T and T/T individuals. For example XBP1 up-regulation may 
reduce EZH2 expression in C/T, but not in C/C patients (lacking XBP1 binding site). 
For other genetic variants, it has been reported that homozygous wild-type and 
heterozygous individuals show identical gene expression levels, while only 
homozygous mutant individuals demonstrate significantly different expression165.  
It is worth noting that other mechanisms may explain the prognostic role of the 
626-394C>T variant in mCRC patients. For example, the 626-394C>T variant is in 
linkage disequilibrium with several other EZH2 polymorphisms142 that may play a 
more determinant functional role. Thus, the in silico prediction needs to be 
mechanistically confirmed. Moreover, the impact of this variant on EZH2 expression 
in CRC cells should be investigated in future studies. 
Reported results show that patients carrying zero, one or two C alleles reported 
a progressively worse PFS, while the same trend was not significant for OS. 
Nonetheless, the worst OS outcome was observed in C/C homozygotes. Since PFS 
more accurately reflects the benefit of first-line treatment than OS, the correlation we 
found in our series may suggest that the polymorphic variant has a main predictive 
effect on treatment benefit. Even though we did not observe significant correlation 
between 626-394C>T polymorphism and treatment activity, this could be partly 
explained by the high RR (64%) in our retrospective series. However, median PFS 
and OS times in our population are in line with those reported in randomized and 
observational trials7 with FOLFIRI plus bevacizumab, thus reducing the risks of 
major selection bias. It is worth noting that comparing the C/C homozygotes with all 
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other genotypes we found a significant association with both PFS and OS. More 
importantly, the C/C genotype emerged as an independent predictor of poorer 
prognosis at multivariate analysis. Moreover, the C/C variant seemed to predict PFS 
and OS with higher sensitivity than other conventional prognostic variables.  
Interestingly, mucinous histology was significantly associated with worse PFS 
and OS at multivariate analysis. These results seem to confirm previous reports 
suggesting the impact of mucinous histology on both benefit from treatment and OS 
in mCRC patients treated with first-line chemotherapy166,167. 
To conclude, this is the first experience suggesting that an EZH2 
polymorphism has significant impact on clinical outcome in oncology. We reported a 
correlation between the 626-394C>T SNP and both PFS and OS in mCRC patients 
treated with the FOLFIRI regimen in first-line. Since we found that only C/C 
genotype is associated with worse prognosis, a major limit of this study is the 
reduced number of C/C individuals evaluated (12 in the FOLFIRI plus bevacizumab 
group and only 2 in the FOLFIRI alone group). We tried to overcome this limit by 
including all 214 patients in a multivariate analysis (Table 3.4). This analysis 
showed that the EZH2 genotype is an independent predictor of clinical outcome in 
mCRC patients treated with the FOLFIRI regimen (with or without bevacizumab). 
Moreover, no significant interaction between the EZH2 genotype and treatment was 
reported: this evidence seems to strengthen a main prognostic value or, on the other 
hand, a potential predictive role in patients receiving irinotecan-based chemotherapy 
(as also suggested by the Oncomine analysis) of the studied EZH2 SNP. However, 
these results need to be confirmed by larger, prospective independent series in order 
to overcome possible bias inherent to retrospective evaluations. In addition, the same 
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SNP should be tested on mCRC patients treated with other regimens (e.g. 
oxaliplatin-based combinations) to discriminate between predictive and prognostic 
power.  
 
 
4.2. Conclusions and future development 
 
The evidence supporting a role for CSCs in solid tumors is fascinating, since it 
opens new frontiers for the development of novel anticancer agents, prediction of 
benefit from treatment and prognostic stratification of patients: the CSC hypothesis 
thus sheds new light on how we interpret carcinogenesis, tumor recurrence and 
mechanisms of resistance to medical treatment. EZH2 is a key element in 
transcriptional regulation of CSCs and therefore is an intriguing candidate for 
translational analysis and drug development. This is the first analysis of the role of 
EZH2 SNPs in mCRC patients treated with first-line chemotherapy: far from being 
conclusive, this pivotal experience leaves some unanswered questions and opens new 
fields of investigation.  
In particular, the hypothesis that allelic variants of the 626-394C>T SNP might 
affect gene transcription (partly supported by the in vivo evaluation of EZH2 mRNA 
levels) should be confirmed by direct measurement of EZH2 protein levels in tumor 
tissue: this analysis will provide conclusive evidence that this SNP variants affect 
EZH2 function through differential protein expression. As previously discussed, 
however, other mechanisms may explain differential function of EZH2 according to 
the 626-394C>T SNP genotype: for example, the in silico characterization suggests 
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that EZH2 binding site to transcription factors may be altered in patients harbouring 
the C variant, thus affecting the functional role of EZH2 in CSCs. Moreover, as 
discussed in the previous chapter, EZH2 levels may be influenced by other 
mechanisms, as well as EZH2 function may be altered by somatic mutations (as 
described in haematologic malignancies). All these alternative mechanisms should be 
further investigated.  
These preliminary data suggest that the 626-394C>T SNP has a main 
prognostic value: SNP evaluation on larger series of mCRC patients treated with 
other chemotherapy regimens than FOLFIRI may therefore be of interest to confirm 
this finding. Even more importantly, adequately powered prospective trials should be 
conducted to definitively validate this parameter as a major prognostic indicator in 
mCRC.  
As discussed in the first chapter, other prognostic molecular biomarkers may 
be of clinical usefulness in mCRC, particularly BRAF V600E mutation. Some 
preliminary laboratory findings suggest that EZH2 is linked to the RAF signalling 
pathway: in fact, Chang et al. found that in breast tumor initiating cells EZH2 
expression-mediated downregulation of DNA damage repair leads to accumulation 
of recurrent RAF1 gene amplification, which in turn activates p-ERK-β-catenin 
signaling to promote breast CSC expansion168. Moving from these preclinical 
evidence and the compelling demonstration that BRAF mutant colorectal tumors 
have a particularly poor prognosis, investigating the correlation of EZH2 expression 
and genotype and BRAF mutational status may be of extreme interest, since it may 
help to clarify the mechanisms underlining the aggressiveness of such cancers and to 
open new options for the treatment of BRAF mutant cases. 
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Finally, recent studies have underlined a potential role of putative CSC 
markers in determining prognosis of patients after radical resection of non-metastatic 
disease. However, these analyses suffer from several limitations, due to inadequate 
sample dimension, technical difficulties and only rough identification of CSC. 
Therefore, adding some bona fide markers of CSC behaviour to “conventional” CSC 
markers might implement the prognostic stratification of radically resected patients. 
Moreover, since CSCs are considered the seeds of metastatic spreading, CSC-based 
biomarkers might identify resistant tumors which are insensitive to adjuvant 
chemotherapy, thus helping clinicians in refining treatment choices. 
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